CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of priority under 35 U.S.C. §119 of U.S. Provisional Application Serial No. 63/089,162 filed on October 8, 2020, the content of which is relied upon and incorporated herein by reference in its entirety.

FIELD

[0002] The present disclosure generally relates to dissolvable cell culture materials and methods of using them. In particular, the present disclosure relates to dissolvable foam scaffolds for cell culture and methods of making and using such dissolvable foam scaffolds, including methods of using them to expand cell cultures using harvesting and reseeding methods.

BACKGROUND

[0003] In-vitro studies are important to the drug discovery process and exploration of potential new therapeutics. However, traditional in-vitro cell culture on two-dimensional (2D) culture substrates fails to simulate an in-vivo environment. Since almost all cells in the in- vivo environment are surrounded by other cells and extracellular matrix (ECM) in a three- dimensional (3D) fashion, 2D cell culture does not adequately simulate the natural 3D environment of cells. Cells in 2D culture are forced to adhere to a rigid surface and are geometrically constrained, adopting a flat morphology which alters the cytoskeleton regulation that is important in intracellular signaling, and consequently can affect cell growth, migration, and apoptosis. Moreover, organization of the ECM, which is significant to cell differentiation, proliferation, and gene expression, is absent in most 2D cells. These limitations of 2D cultures often result in biological responses in-vitro that are strikingly different from what is observed in-vivo.

[0004] Currently, in drug discovery, the standard procedure of screening compounds starts with 2D cell culture-based tests, followed by animal model tests, and then clinical trials. According to publicly available data, only about 10% of the compounds progress successfully through clinical development. Many drugs fail during clinical trials (especially during phase III, which is the most expensive phase of clinical development) largely due to the lack of clinical efficacy and/or unacceptable toxicity. A portion of these failures is attributed to data collected from the 2D culture tests in which the cellular response to drug(s) is altered due to their unnatural microenvironment. Due to the high costs associated with drug discovery, demand has risen for the ability to dismiss ineffective and/or unacceptable toxic compounds as early in the drug discovery process as possible. In-vitro cell-based systems that can more realistically mimic the in-vivo cell behaviors and provide more predictable results to in-vivo tests are presently being considered.

[0005] Recent research suggests that 3D cell culture, in contrast to 2D culture, more accurately represents the environment experienced by cells in-vivo, and it has been demonstrated that cell responses in 3D cultures are more similar to in-vivo behavior than the cell responses in 2D cultures. The additional dimensionality of 3D cultures is believed to lead to the differences in cellular responses because not only does it influence the spatial organization of the cell surface receptors engaged in interactions with surrounding cells, but it also induces physical constraints to cells. These spatial and physical aspects in 3D cultures are believed to affect the signal transduction from the outside to the inside of cells, and ultimately influence gene expression and cellular behavior.

[0006] The benefits of 3D culture have influenced the development of cell culture technologies which simulate the natural 3D environment of cells. Some bioreactors include a carrier in the form of a stationary packing material forming a fixed or packed bed for promoting cell adhesion and growth. The arrangement of the packing material of the fixed bed affects local fluid, heat, and mass transport, and usually is very dense to maximize cell cultivation in a given space. Yet another 3D cell culture technology is a porous 3D matrix or scaffold which promotes the growth and proliferation of the cultured cells within pores and other interior spaces of the matrix.

[0007] In each of the above described technologies, a protease treatment may be used to harvest the cells. However, commonly used harvesting procedures, such as protease treatment, subject the cells to harsh conditions which may damage cell structure and function. Additionally, protease treatment alone often causes only a limited amount of cell detachment. For the fixed bed material, the problem, in part, results from the densely packed nature of the fixed bed material which makes it more difficult to circulate the protease agent throughout the bed and increase the yield of cells harvested. Similarly, it can be difficult to circulate the protease agent through interior spaces of the 3D matrix, which in turn makes it difficult to dislodge cells during the harvest process. This difficulty is compounded by the presence of extracellular macromolecules secreted by the cultured cells that serve to attach the cells to the surface of the fixed bed material or to the surface of the matrix.

[0008] Either alternatively, or in combination with the protease treatment, methods and systems for harvesting cells have been developed that apply mechanical force to release cultured cells from the fixed bed material or the 3D matrix. For example, the fixed bed material or the 3D matrix, or a larger system including the fixed bed material or the 3D matrix, may be shaken or vibrated to release the cultured cells. Application of mechanical force may also cause physical damage to the cultured cells, which in turn reduces cell culture yields.

[0009] Existing packed bed substrates are generally made from unwoven plastic fibers or mats offering surface to volume ratios that are large compared to 2D surfaces. A down-side to these substrates, however, is the difficulty or impossibility to efficiently harvest intact and/or viable cells from them, as described above. Also, in order to start a cell culture in a packed bed reactor, a number of cells in relation with the available surface must be introduced in the setup. For large surface areas, the number of cells required to do so cannot be banked and an amplification of a cell population from the vial stored in the working cell bank is required. For adherent cells, this amplification is generally done using classical cell culture plates flasks or bottle and use multiple steps as described in the procedure for seed train preparation for iCellis 500/200 M2 bioreactor, as detailed in application note USD 3095 from Pall Life Sciences, entitled “Bringing Fast Process Development to Adherent Cell Culture Processes: Demonstration of Linear Scalability from 1.6 to 200 m ² in Single-Use Fixed Bed Bioreactor (available at https://www.pall.com/content/dam/pall/biopharm/ht- library/non-gated/application-notes/15.6399_USD3095_iCELLis_ 500_AN_EN.pdf).

[0010] However, an issue with the current seed train method (for example, the one described in the Pall application note USD 3095) is that the cell population is amplified on a different surface from the final one used in the packed bed reactor, which could result in an adaptation phase of the cells and an alteration of overall performance. [0011] Accordingly, efficient cell culture surfaces and improved seed train methods for expanding cell populations on such cell culture surfaces are needed.

SUMMARY

[0012] According to embodiments disclosed herein, a method of cell seed train expansion is provided. The method includes providing a first cell culture substrate of a dissolvable foam scaffold, and delivering cells and a cell culture media to the first cell culture substrate, the cells being seeded on or in the dissolvable foam scaffold of the first cell culture substrate. The method further includes controlling environmental conditions and composition of the cell culture media to promote culturing of the cells on the first cell culture substrate, and then dissolving the dissolvable foam scaffold of the first cell culture substrate to form a solution containing the cells. The method further includes harvesting the cells from the solution, and reseeding at least a portion of the cells that were harvested onto a second cell culture substrate of the dissolvable foam scaffold, wherein the dissolvable foam scaffold of the first cell culture substrate is the same material as the dissolvable foam scaffold of the second cell culture substrate.

[0013] According to aspects of embodiments, the method can include delivering cell culture media to the second cell culture substrate; and controlling environmental conditions and composition of the cell culture media to promote culturing of the cells in the dissolvable foam scaffold of the second cell culture substrate. The dissolvable foam scaffold of the second cell culture substrate can be dissolved and cell harvested therefrom. The method can further include reseeding at least a portion of the cells that were harvested from the second cell culture substrate onto a third cell culture substrate of the dissolvable foam scaffold, wherein the dissolvable foam scaffold of the third cell culture substrate is the same material as the dissolvable foam scaffold of the second cell culture substrate.

[0014] According to some embodiments, the cells are seeded on the first cell culture substrate such that the cells enter pores of the dissolvable foam scaffold. The dissolvable foam scaffold can be disposed in a container configured to hold the cell culture media. The container can be a perfusion bioreactor.

[0015] According to some embodiments, the method a volume of the second cell culture substrate is greater than a volume of the first cell culture substrate. Further, a volume of the third cell culture substrate is greater than the volume of the second cell culture substrate.

[0016] According to aspects of some embodiments, the dissolvable foam scaffold includes an ionotropically crosslinked polygalacturonic acid compound selected from at least one of: pectic acid; partially esterified pectic acid, partially amidated pectic acid and salts thereof; and at least one first water-soluble polymer having surface activity.

[0017] According to some embodiments, a method of cell seed train expansion for scaling a cell sample to a production scale reactor is provided herein. The method includes expanding the cell sample containing cells on a first dissolvable foam scaffold; expanding at least a portion of the cells harvested from the first dissolvable foam scaffold onto a second dissolvable foam scaffold; and seeding at least a portion of the cells harvested from at least one of the first dissolvable foam scaffold and the second dissolvable foam scaffold onto a third dissolvable foam scaffold. Wherein the first, second, and third dissolvable foam scaffold comprise the same scaffold material.

[0018] Additional features and advantages will be set forth in the detailed description which follows, and in part will be readily apparent to those skilled in the art from that description or recognized by practicing the embodiments as described herein, including the detailed description which follows, the claims, as well as the appended drawings.

[0019] It is to be understood that both the foregoing general description and the following detailed description are merely exemplary and are intended to provide an overview or framework to understanding the nature and character of the claims. The accompanying drawings are included to provide a further understanding and are incorporated in and constitute a part of this specification. The drawings illustrate one or more embodiment(s), and together with the description serve to explain principles and operation of the various embodiments.

BRIEF DESCRIPTION OF THE DRAWINGS

[0020] The disclosure will be understood more clearly from the following description and from the accompanying figures, given purely by way of non-limiting example, in which: [0021] Figure 1 is an illustration of a seed train method for the seeding of a production-scale reactor using 2D surfaces for the production of the cell mass needed to seed a production reactor.

[0022] Figure 2 is an illustration of a seed train method for the seeding of a production-scale reactor using increasing volumes of dissolvable scaffolds for the production of the cell mass needed to seed a production reactor, according to embodiments of this disclosure.

[0023] Figure 3 is a perspective view of a dissolvable foam scaffold in accordance with the present disclosure.

[0024] Figure 4 shows an SEM picture of a foam scaffold prepared in Example 1.

[0025] Figure 5 shows an SEM picture of a foam scaffold prepared in Example 2.

[0026] Figure 6 shows an SEM picture of a foam scaffold prepared in Example 3.

[0027] Figure 7 shows an SEM picture of a foam scaffold prepared in Example 4.

[0028] Figure 8 shows an SEM picture of a foam scaffold prepared in Example 5.

[0029] Figure 9 shows an SEM picture of a foam scaffold prepared in Example 6.

[0030] Figure 10 shows an SEM picture of a foam scaffold prepared in Example 7.

[0031] Figure 11 shows an SEM picture of a foam scaffold prepared in Example 8.

[0032] Figure 12 shows an SEM picture of a foam scaffold prepared in Example 9.

[0033] Figure 13 shows an SEM picture of a foam scaffold prepared in Example 10.

[0034] Figure 14 shows an SEM picture of a foam scaffold prepared in Example 11.

[0035] Figure 15 shows four foams prepared in Example 12 where varied amounts of a plasticizer were added to form the four foam scaffolds.

[0036] Figure 16 shows an SEM picture of a foam scaffold prepared in Example 13. [0037] Figure 17 shows spheroids formed in the pores of a foam scaffold prepared in Example 4.

[0038] Figure 18 shows cells adhered to the foam scaffold prepared in Example 14.

[0039] Figure 19 shows cells adhered to the foam scaffold prepared in Example 15.

[0040] Figure 20 shows cells after six days of expansion adhered to the foam scaffold prepared in Example 15.

[0041] Figure 21 is a bar graph showing the GFP-positive percentage of transfected HEK cells for each of the culture conditions of Example 24.

[0042] Figure 22 is a bar graph showing GFP-positive percentage of transfected cells per set of foam scaffold of Example 25.

[0043] Figure 23 is a bar graph showing the number of viral particles (vp) per set of foam scaffold of Example 25.

[0044] Figure 24 is a bar graph showing the number of viral particles per cell obtained per set of foam scaffold of Example 25.

[0045] Figure 25 is a bar graph showing the fraction of cells exhibiting GFP expression for each of the sets of foam scaffolds of Example 25 after infection.

[0046] Figure 26 is an illustration of an experimental design to investigate the impact of previous cell culture conditions on cell growth performance, transfection efficiency, and viral vector production performance.

[0047] Figure 27 is a bar graph showing cell growth performance on CellBIND® surface of cells previously grown for one (pl) or two (p2) passages in PGA scaffolds compared to cells previously grown on CellBIND® (2D).

[0048] Figure 28 is a bar graph showing cell growth performance in dissolvable PGA scaffolds of cells previously grown for one (pl) or two (p2) passages in PGA scaffolds compared to cells previously grown on CellBIND® (2D). [0049] Figure 29 shows fluorescence microscopy images of GFP expression for cells from the different origins (2D, pl and p2) transfected in 2D conditions (upper lane) or in dissolvable scaffolds (lower lane) 3 days after transfection.

[0050] Figure 30 is a bar graph showing GFP expression of pl and p2 cells at harvest time, after transfection on CellBIND®, reported to GFP expression ratio of cell previously grown in 2D.

[0051] Figure 31 is a bar graph showing GFP expression of pl and p2 cells at harvest time after transfection in dissolvable scaffolds, reported to GFP expression ratio of cell previously grown in 2D.

[0052] Figure 32 is a bar graph showing viral particle/cell production on CellBIND® of pl and p2 cells compared to the VP/cell production of 2D cells.

[0053] Figure 33 is a bar graph showing viral particle/cell production in dissolvable scaffolds of pl and p2 cells compared to the VP/cell production of 2D cells.

[0054] Figure 34 is a graph of cell number over days during a seed train method according to embodiments of this disclosure.

[0055] Figure 35 is a graph of the fold expansion of cells from the seed train of Figure 34.

DETAILED DESCRIPTION

[0056] Reference will now be made in detail to the present embodiment(s), an example(s) of which is/are illustrated in the accompanying drawings. Whenever possible, the same reference numerals will be used throughout the drawings to refer to the same or like parts.

[0057] The singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise. The endpoints of all ranges reciting the same characteristic are independently combinable and inclusive of the recited endpoint. All references are incorporated herein by reference. [0058] As used herein, “have,” “having,” “include,” “including,” “comprise,” “comprising” or the like are used in their open-ended sense, and generally mean “including, but not limited to.”

[0059] All scientific and technical terms used herein have meanings commonly used in the art unless otherwise specified. The definitions provided herein are to facilitate understanding of certain terms used frequently herein and are not meant to limit the scope of the present disclosure.

[0060] The present disclosure is described below, at first generally, then in detail on the basis of several exemplary embodiments. The features shown in combination with one another in the individual exemplary embodiments do not all have to be realized. In particular, individual features may also be omitted or combined in some other way with other features shown of the same exemplary embodiment or else of other exemplary embodiments.

[0061] To overcome the inefficiencies in existing cell culture surfaces and seed train methods, embodiments of the present disclosure use a dissolvable scaffold as a substrate for the packed bed. Using this substrate, it is possible to quickly and easily harvest the totality of the cell population with a minimum stress for the cells and without having to use protease.

Cells from a working cell bank can then be expanded in initial steps in increasing volumes of dissolvable scaffolds until the adequate number of cells required to seed the final reactor is reached. This method allows an important scale up of the cell culture with a minimal impact on the cells and avoids the above-discussed stress to cell populations that occurs when the seed train transitions an expanded cell culture from one type of surface to another (i.e., inefficiencies from cells from one surface having to adapt to a new, different type of surface).

[0062] As used herein, “seed train” refers to the practice of running cells through multiple cultivation cycles and/or system to grow the cell population with each passage. The purpose of a seed train is the generation of an adequate number of cells for the inoculation of a production bioreactor. The production bioreactor is inoculated out of the largest seed train scale. The seed train steps have a significant impact on the product titer and cell growth in production scale, as well as the success and reproducibility of the seed train itself.

[0063] One or more embodiments of this disclosure relate to methods that produce a cell population sufficient to seed a packed bed production-scale bioreactor, where the packed bed is composed of a dissolvable 3D substrate material. The packed bed can be, for example, a foam or a fiber mat. As described further below, the dissolvable foam scaffolds as described herein include at least one ionotropically crosslinked polysaccharide. Generally, polysaccharides possess attributes beneficial to cell culture applications. Polysaccharides are hydrophillic, non-cytotoxic and stable in culture medium. Examples include pectic acid, also known as polygalacturonic acid (PGA), or salts thereof, partly esterified pectic acid or salts thereof, or partly amidated pectic acid or salts thereof. Pectic acid can be formed via hydrolysis of certain pectin esters. Pectins are cell wall polysaccharides and in nature have a structural role in plants. Major sources of pectin include citrus peel (e.g., peels from lemons and limes) and apple peel. Pectins are predominantly linear polymers based on a 1,4-linked alpha-D-galacturonate backbone, interrupted randomly by 1,2-linked L-rhamnose. The average molecular weight ranges from about 50,000 to about 200,000 Daltons.

[0064] The dissolvable scaffolds can be made with or without functionalization (e.g., grafting/coating) of alginate, of starch, or of foamy protein dissolvable by an enzyme. Traditionally, cells are initially expanded on 2D surface until the needed number of cells is reached, and cells are then harvested using proteases and the desirable number of cells is seeded in the packed bed material. However, in methods of the present disclosure, cells are seeded in a small volume of the dissolvable scaffold, which is used as a packed-bed material in a bioreactor and expanded for a given time. The scaffold is then dissolved, and the cells released are harvested and reseeded in an increased volume of the same dissolvable material until the desirable cell number required to seed the production-scale reactor is reached.

[0065] While a dissolvable scaffold can be used in both the seed train and the production scale reactor, methods of this disclosure can include a production reactor with a different type of cell culture substrate.

[0066] The methods of this disclosure having significant advantages over existing seed train and scale up methods. For one, the cells used in methods of the present disclosure do not need to adapt to a new substrate surface — the so-called problem of adaptation. That is, traditionally, if a cell population is started on a 2D surface at the initial stage(s) of the seed train, when the expanded population is passed to a 3D substrate or another type of substrate surface that differs from the 2D surface of the initial stage(s), the cell culture will experience some type of inefficiency (e.g., a slow down in cell growth and expansion, or a negative impact on viral vector production). As will be discussed below, methods of this disclosure can overcome this adaptation problem, including avoiding the decrease in viral vector production. These advantages can increase efficiency by minimizing lag time and adaptation time after reseeding onto a larger volume substrate.

[0067] Additionally, advantages include reductions in footprints for the cell culture components or systems to produce the desired numbers of cells for production-scale reactor seeding. For instance, the 3D scaffold can produce more cells per area of reactor footprint compared to a 2D surface. In addition, the 3D scaffolds can be used in fewer vessels — even a single vessel — and thus can reduce labor requirements and risk of contamination. There may be other advantages, as well, including avoiding the use of protease or mechanical forces (e.g., vibrations) during harvest. Indeed, the dissolvable scaffolds of this disclosure can allow harvesting cells without protease, if desired, and without mechanical agitation. Eliminating these conditions from cell harvesting can improve the quality and viability of harvested cells, and may also improve the yield of harvested cells. For example, according to embodiments of this disclosure, 100% of cells may be harvested, compared to 90% or less of cells when using protease (e.g., trypsin) and/or vibration.

[0068] Figures 1 and 2 represent a standard seed train process and a seed train according to embodiments of this disclosure, respectively. In Figure 1, after cells are thawed from a cell bank, cells are expanded on 2D surfaces at each step 1-3. With each subsequent step, the two-dimensional surface needed increases and quickly results in a large footprint of 2D surface vessels. For example, Table 1 below shows the number of 2D flasks (Coming® CellBIND® 225 cm ² T-Flasks) are needed at steps 1, 2, and 3 of Figure 1. In contrast, Figure 2 shows a method in which a dissolvable 3D scaffold is used in each of steps 1, 2, and 3. The volumes of scaffold required at steps 1, 2, and 3 are 25 mL, 500 mL, and 10 L, as summarized in Table 1. Thus, embodiments of the current disclosure result in significant footprint savings compared to a 2D seed train. In addition, according to the standard seed train in Figure 1, the cells may need to be passed from the 2D surface in step 3 to another surface in the production-scale vessel of step 4. As discussed herein, this cell passage between different culture surfaces can result in a cell adaptation phase that negatively impacts cell growth and/or viral vector production and efficiency. In contrast, as shown in Figure 2, embodiments of the current disclosure can avoid the negative impacts of cell adaptation by using the same 3D dissolvable scaffold in all of steps 1-4. As discussed below, this results in improved cell culture performance, viral vector production, and other advantages. Further details of the method in Figure 2 are described in the examples below, including Example 27.

Table 1. The scaffold volume needed when using a 3D dissolvable scaffold according to embodiments of this disclosure (Figure 2) compared to the surface area required using a 2D cell culture surface according to standard seed train (Figure 1).

[0069] Embodiments of the present disclosure relate to dissolvable foam scaffolds for cell culture and methods of making such dissolvable foam scaffolds. Embodiments of the present disclosure further relate to methods of cell culture of adherent cells, cell aggregates, or spheroids, in dissolvable foam scaffolds. Furthermore, embodiments of the present disclosure relate to bioreactors systems including dissolvable foam scaffolds. As will become clearer in the discussions below, foam scaffolds as disclosed herein are described as being dissolvable and insoluble. As used herein, the term “insoluble” is used to refer to a material or combination of materials that is not soluble, and that remains crosslinked, under conventional cell culture conditions which include, for example, cell culture media. Also as used herein, the term “dissolvable” is used to refer to a material or combination of materials that is digested when exposed to an appropriate concentration of an enzyme that digests or breakdowns the material or combination of materials. Dissolvable foam scaffolds as described herein are porous scaffolds having an open pore architecture and highly interconnected pores. The pores of the scaffolds provide a protected environment for the culturing of cells where the cell-to-cell interactions and formation of ECM in a 3D fashion are aided. The dissolvable foam scaffolds may be completely digested which allows for harvesting cells without damaging the cells using protease treatment and/or mechanical harvesting techniques.

[0070] Figure 3 is a perspective view of a dissolvable foam scaffold 100 in accordance with the present disclosure. As will be described in further detail below and as will become more clear from the other figures of the present disclosure, dissolvable foam scaffold 100 is a porous foam that includes an open pore architecture. Dissolvable foam scaffold 100 has a porosity of from about 85% to about 96% and an average pore size diameter of between about 50 pm and about 500 pm. Dissolvable foam scaffold 100 provides a protected environment within the pores of the foam scaffold for the culturing of cells. Additionally, dissolvable foam scaffold 100 is also dissolvable when exposed to an appropriate enzyme that digests or breakdowns the material which facilitates harvesting of the cells cultured in the scaffold without damaging the cells.

[0071] Dissolvable foam scaffolds as described herein include at least one ionotropically crosslinked polysaccharide. Generally, polysaccharides possess attributes beneficial to cell culture applications. Polysaccharides are hydrophillic, non-cytotoxic and stable in culture medium. Examples include pectic acid, also known as polygalacturonic acid (PGA), or salts thereof, partly esterified pectic acid or salts thereof, or partly amidated pectic acid or salts thereof. Pectic acid can be formed via hydrolysis of certain pectin esters. Pectins are cell wall polysaccharides and in nature have a structural role in plants. Major sources of pectin include citrus peel (e.g., peels from lemons and limes) and apple peel. Pectins are predominantly linear polymers based on a 1,4-linked alpha-D-galacturonate backbone, interrupted randomly by 1,2-linked L-rhamnose. The average molecular weight ranges from about 50,000 to about 200,000 Daltons.

[0072] The polygalacturonic acid chain of pectin may be partly esterified, e.g., methyl groups and the free acid groups may be partly or fully neutralized with monovalent ions such as sodium, potassium, or ammonium ions. Polygalacturonic acids partly esterified with methanol are called pectinic acids, and salts thereof are called pectinates. The degree of methylation (DM) for high methoxyl (HM) pectins can be, for example, from 60 to 75 mol% and those for low methoxyl (LM) pectins can be from 1 to 40 mol%. The degree of esterification of partly esterified polygalacturonic acids as described herein may be less than about 70 mol%, or less than about 60 mol%, or less than 50 mol%, or even less than about 40 mol%, and all values therebetween. Without wishing to be bound by any particular theory, it is believed that a minimum amount of free carboxylic acid groups (not esterified) facilitates a degree of ionotropic crosslinking which allow for the formation of a dissolvable scaffold which is insoluble. [0073] Alternatively, the polygalacturonic acid chain of pectin may be partly amidated. Polygalacturonic acids partly ami dated pectin may be produced, for example, by treatment with ammonia. Amidated pectin contains carboxyl groups (-COOH), methyl ester groups (-COOCHs), and amidated groups (-CONH2). The degree of amidation may vary and may be, for example, from about 10% to about 40% amidated.

[0074] According to embodiments of the present disclosure, dissolvable foam scaffolds as described herein may include a mixture of pectic acid and partly esterified pectic acid. Blends with compatible polymers may also be used. For example, pectic acid and/or partly esterified pectic acid may be mixed with other polysaccharides such as dextran, substituted cellulose derivatives, alginic acid, starches, glycogen, arabinoxylans, agarose, etc. Glycosaminoglycans like hyaluronic acid and chondroitin sulfate, or various proteins such as elastin, fibrin, silk fibroin, collagen and their derivatives can be also used. Water soluble synthetic polymers can be also blended with pectic acid and/or partly esterified pectic acid. Exemplary water-soluble synthetic polymers include, but are not limited to, polyalkylene glycol, poly(hydroxyalkyl(meth)acrylates), poly(meth)acrylamide and derivatives, poly(N- vinyl-2-pyrrolidone), and polyvinyl alcohol.

[0075] According to embodiments of the present disclosure, dissolvable foam scaffolds as described herein may further include at least one first polymer. The at least one first polymer is water soluble, non-ionotropically crosslinkable and has surface activity. As used herein, the term “surface activity” refers to the activity of an agent to lower or eliminate the surface tension (or interfacial tension) between two liquids or between a liquid and a solid or between gas and liquid. The at least one first polymer may have a hydrophilic-lipophilic balance (HLB) of greater than about 8 or even greater than about 10. For example, the at least one first polymer may have an HLB of between about 8 and about 40 or between about 10 and about 40. The at least one first polymer may have an HLB of between about 8 and about 15, or even between about 10 and about 12. HLB provides a reference for the lipophilic or hydrophilic degree of a polymer. A larger HLB value indicates stronger hydrophilicity, while a smaller HLB value indicates a stronger lipophilicity. In general, the HLB value varies in the range of from 1 to 40 and the hydrophilic-lipophilic transition is often considered to be between about 8 and about 10. When the HLB value is less than the hydrophilic-lipophilic transition, the material is lipophilic, and when the HLB value is greater than the hydrophilic- lipophilic transition the material is hydrophilic.

[0076] Exemplary first polymers in accordance with embodiments of the present disclosure may be any of cellulose derivatives, proteins, synthetic amphiphilic polymers, and combinations thereof. Exemplary cellulose derivatives include, but are not limited to, hydroxyethylcellulose (HEC), hydroxypropylcellulose (HPC), methylcellulose (MC), hydroxyethylmethylcellulose (HEMC), and hydroxypropyl-methylcellulose (HPMC). Exemplary proteins include, but are not limited to, bovine serum albumin (BSA), gelatine, casein and hydrophobins. Exemplary synthetic amphiphilic polymers include, but are not limited to, a poloxamer available under the trade name Synperonics® (commercially available from Croda International, Snaith, United Kingdom), a poloxamer available under the trade name Pluronics® (commercially available from BASF Corp., Parsippany, NJ) and a poloxamer available under the trade name Kolliphor® (commercially available from BASF Corp., Parsippany, NJ).

[0077] Dissolvable foam scaffolds as described herein may further include at least one second polymer. The at least one second polymer is water soluble and has no surface activity. Exemplary second polymers may be any of synthetic polymers, semisynthetic polymers, natural polymers and combinations thereof. Exemplary synthetic polymers include, but are not limited to, polyethylene glycol, polyvinyl pyrrolidone, polyvinyl alcohol, carboxyvinyl polymer, polyacrylic acid, polyacrylamide, homopolymer and copolymer of N- (2 -Hydroxypropyl) methacrylamide, polyvinyl methyl ether-maleic anhydride, and polyethylene oxide/polypropylene oxide block copolymers. Exemplary semisynthetic polymers include, but are not limited to, dextran derivatives, carboxymethyl cellulose, hydroxyethyl cellulose and derivatives, methylcellulose and derivatives, ethylcellulose cellulose, ethyl hydroxyethyl cellulose, and hydroxypropyl cellulose. Exemplary natural polymers include, but are not limited to, starch and starch derivatives, polymers obtained by microbial fermentation such as curdlan, pullulan and gellan gum, xanthan gum, dextran, proteins such as albumin, casein and caseinates, gelatin, seaweed extracts such as agar, alginates and carrageenan, seed extracts such as guar gum and derivatives and locust bean gum, hyaluronic acid, and chondroitin sulfate. [0078] Dissolvable foam scaffolds as described herein may be crosslinked to increase their mechanical strength and to prevent the dissolution of the scaffolds when placed in contact with cell culture medium. Crosslinking may be performed by ionotropic gelation as described below wherein ionotropic gelation is based on the ability of poly electrolytes to crosslink in the presence of multivalent counter ions to form crosslinked scaffolds. Without wishing to be bound by any particular theory, it is believed that ionotropic gelation of the polysaccharide of the dissolvable foam scaffolds is the result of strong interactions between divalent cations and the polysaccharide.

[0079] According to embodiments of the present disclosure, scaffolds as described herein are porous foam scaffolds. Foam scaffolds as described herein may have a porosity of from about 85% to about 96%. For example, foam scaffolds as described herein may have a porosity of from about 91% to about 95%, or about 94% to about 96%. As used herein, the term “porosity” refers to the measure of open pore volume in the dissolvable scaffold and is referred to in terms of % porosity, wherein % porosity is the percent of voids in the total volume of the dissolvable foam scaffold. Foam scaffolds as described herein may have an average pore size diameter of between about 50 pm and about 500 pm. For example, average pore size diameter may be between about 75 pm and about 450 pm, or between about 100 pm and about 400 pm, or even between 150 pm and about 350 pm and all values therebetween.

[0080] Scaffolds as described herein may have a wet density of less than about 0.40 g/cc. For example, scaffolds as described herein may have a wet density of less than about 0.35 g/cc, or less than about 0.30 g/cc, or less than about 0.25 g/cc. Scaffolds as described herein may have a wet density of between about 0.16 g/cc and about 0.40 g/cc, or between about 0.16 g/cc and about 0.35 g/cc, or between about 0.16 g/cc and about 0.30 g/cc, or even between about 0.16 g/cc and about 0.25 g/cc, and all values therebetween. Scaffolds as described herein may have a dry density of less than about 0.20 g/cc. For example, scaffolds as described herein may have a dry density of less than about 0.15 g/cc, or less than about 0.10 g/cc, or less than about 0.05 g/cc. Scaffolds as described herein may have a dry density of between about 0.02 g/cc and about 0.20 g/cc, or between about 0.02 g/cc and about 0.15 g/cc, or between about 0.02 g/cc and about 0.10 g/cc, or even between about 0.02 g/cc and about 0.05 g/cc, and all values therebetween. [0081] Several pore types are possible in scaffolds. Open pores allow for cellular access on both sides of the scaffold and allow for liquid flow and transport of nutrients through the dissolvable scaffold. Partially open pores allow for cellular access on one side of the scaffold, but mass transport of nutrients and waste products is limited to diffusion. Closed pores have no openings and are not accessible by cells or by mass transport of nutrients and waste products. Dissolvable foam scaffolds as described herein have an open pore architecture and highly interconnected pores. Generally, the open pore architecture and highly interconnected pores enable migration of cells into the pores of the dissolvable foam scaffolds and also facilitate enhanced mass transport of nutrients, oxygen and waste products. The open pore architecture also influences cell adhesion and cell migration by providing a high surface area for cell-to-cell interactions and space for ECM regeneration.

[0082] Dissolvable foam scaffolds as described herein are digested when exposed to an appropriate enzyme that digests or breakdowns the material. Non-proteolytic enzymes suitable for digesting the foam scaffolds, harvesting cells, or both, include pectinolytic enzymes or pectinases, which are a heterogeneous group of related enzymes that hydrolyze the pectic substances. Pectinases (polygalacturonase) are enzymes that break down complex pectin molecules to shorter molecules of galacturonic acid. Commercially available sources of pectinases are generally multi-enzymatic, such as Pectinex™ ULTRA SP-L (commercially available fromNovozyme North American, Inc., Franklinton, NC), a pectolytic enzyme preparation produced from a selected strain of Aspergillus aculeatus. Pectinex™ ULTRA SP- L contains mainly polygalacturonase, (EC 3.2.1.15) pectintranseliminase (EC 4.2.2.2) and pectinesterase (EC: 3.1.1.11). The EC designation is the Enzyme Commission classification scheme for enzymes based on the chemical reactions the enzymes catalyze.

[0083] According to embodiments of the present disclosure, digestion of the dissolvable foam scaffolds also includes exposing the scaffold to a divalent cation chelating agent. Exemplary chelating agents include, but are not limited to, ethylenediaminetetraacetic acid (EDTA), cyclohexanediaminetetraacetic (CDTA), ethylene glycol tetraacetic acid (EGTA), citric acid and tartaric acid.

[0084] The time to complete digestion of dissolvable foam scaffolds as described herein may be less than about 1 hour. For example, the time to complete digestion of foam scaffolds may be less than about 45 minutes, or less than about 30 minutes, or less than about 15 minutes, or between about 1 minute and about 25 minutes, or between about 3 minutes and about 20 minutes, or even between about 5 minutes and about 15 minutes.

[0085] According to embodiments of the present disclosure, scaffolds as described herein may further include an adhesion polymer coating. The adhesion polymer may include peptides. Exemplary peptides may include, but are not limited to BSP, vitronectin, fibronectin, laminin, Type I and IV collagen, denatured collagen (gelatin), and like peptides, and mixtures thereof. Additionally, the peptides may be those having an RGD sequence. The coating may be, for example, Synthemax® II-SC (commercially available from Coming, Incorporated, Coming, NY). Optionally, the adhesion polymer may include an extracellular matrix. The coating may be, for example, Matrigel® (commercially available from Coming, Incorporated, Coming, NY).

[0086] According to embodiments of the present disclosure, methods for forming dissolvable foam scaffolds as described herein are also disclosed. Methods as described herein may include forming a first aqueous mixture which includes dissolving a polysaccharide in an aqueous solution. Polysaccharides may be those as described above, such as pectic acid or salts thereof, partly esterified pectic acid or salts thereof, or partly amidated pectic acid or salts thereof, and blends of such polysaccharides.

[0087] Methods for forming dissolvable foam scaffolds as described herein may further include forming a second aqueous mixture including a water insoluble divalent metal salt in an aqueous solution. Metals of the divalent metal salts may include, but are not limited to, magnesium, calcium, zinc, strontium, barium, and like cations, and combinations thereof. Anions of the divalent metal salts may include, but are not limited to, oxalates, tartrates, phosphates, carbonates, citrates, and like organic and inorganic anions, and combinations thereof.

[0088] According to embodiments of the present disclosure, forming a second aqueous mixture may further include adding the at least one first polymer as described above to the second aqueous mixture. Optionally, methods as described herein may further include adding the at least one second polymer as described above to the second aqueous mixture. According to embodiments of the present disclosure, the at least one first polymer and the at least one second polymer may be added to the second aqueous mixture separately or may be added to the second aqueous mixture together. When added as a mixture, the mixture may include about 50% of the at least one first polymer and about 50% of the at least one second polymer. For example, the mixture may include between about 35% and about 65% (and all values therebetween) of the at least one first polymer and between about 35% and about 65% (and all values therebetween) of the at least one second polymer.

[0089] According to embodiments of the present disclosure, forming a second aqueous mixture may further include adding a water-soluble plasticizer to the second aqueous mixture. Plasticizers as described herein are non-toxic and do not affect the solubility of the polysaccharides of the dissolvable foam scaffolds. A plasticizer provides flexibility and softness to the resulting foam such that the resulting foam is soft and pliable. Plasticizers as described herein may include, but are not limited to, polyhydric alcohols such as glycerol, sorbitol, ethylene glycol, propylene glycol, polyethylene glycol and combinations thereof. Adding a water soluble plasticizer to the second aqueous mixture may include adding less than about 55 wt. % of the total solid additives added to form the second aqueous mixture. For example, adding a water soluble plasticizer to the second aqueous mixture may include adding less than about 50 wt. %, or less than about 40 wt. %, or less than about 30 wt. %, or less than about 25 wt. %, or between about 15 wt. % and about 55 wt. % ,or between about 15 wt. % and about 50 wt. %, or between about 15 wt. % and about 40 wt. %, or between about 15 wt. % and about 30 wt. %, or between about 15 wt. % and about 25 wt. % of the total solid additives added to form the second aqueous mixture, and all values therebetween. As used herein, the term “total solid additives added to form the second aqueous mixture” refers to all of the components of the aqueous mixture except for water.

[0090] According to embodiments of the present disclosure, forming a second aqueous mixture may further include adding an emulsifying agent to the second aqueous mixture. Emulsifying agents as described herein may include, but are not limited to, Tween® 20, Tween® 80 (each commercially available from commercially available from Croda International, Snaith, United Kingdom).

[0091] According to embodiments of the present disclosure, forming a second aqueous mixture may further include adding at least one leachable solid to the second aqueous mixture. Leachable solids as described herein include materials that reinforce or create pores during the formation of the foam scaffold. Leachable solids may be, but are not limited to, nontoxic leachable materials such as salts, biocompatible mono and disaccharides and water-soluble proteins. Exemplary salts include, but are not limited to, sodium chloride, potassium chloride, calcium chloride, sodium tartrate, sodium citrate, and the like. Exemplary biocompatible mono and disaccharides include, but are not limited to, glucose, fructose, dextrose, maltose, lactose and sucrose. Exemplary water-soluble proteins include, but are not limited to, gelatin and agarose.

[0092] Each of the materials described above in relation to the second aqueous mixture may all be optionally added to the second aqueous mixture and may be added to the second aqueous mixture in any order with the possibility that two or more of the materials may be added to the second aqueous mixture simultaneously. In one exemplary method, forming a second aqueous mixture includes adding a leachable solid to an aqueous solution including a divalent metal salt and mixing the aqueous mixture to facilitate the dissolution of the leachable solid dissolves in the aqueous mixture. The at least one first polymer, the at least one second polymer and/or the water-soluble plasticizer are subsequently added to the second aqueous mixture.

[0093] Methods for forming a dissolvable foam scaffold as described herein may further include, subsequent to forming the first and second aqueous mixtures, combining the second aqueous mixture with the first aqueous mixture to form a combined aqueous mixture. A foam may be formed from the combined aqueous mixture by introducing gas bubbles into the aqueous mixture through mixing, beating, agitating, aerating, whipping, injecting or other mechanical actions. The gas may be for example, but not limited to, air, nitrogen, helium, hydrogen, argon, carbon dioxide or other inert gas. Introducing gas bubbles into the combined aqueous mixture may then be done for a period of less than about 30 minutes, for example, between about 1 minute and about 30 minutes, or between about 3 minutes and about 25 minutes, or even between about 5 minutes and about 20 minutes. While introducing gas bubbles into the combined aqueous mixture, the method for forming a dissolvable foam scaffold may further include adding a gel inducing agent to the combined aqueous mixture. The gel inducing agent may be an acid that provides a buffering action and/or materials that slowly generate acid. Exemplary acids include, but are not limited to, lactic acid lactone, glycolic acid lactone, glucono delta lactone and acid anhydrides. [0094] Methods for forming a dissolvable foam scaffold as described herein may further include, coating the dissolvable foam scaffold with an adhesion polymer coating. Coating the dissolvable foam scaffold may include exposing the scaffold to an aqueous solution having an adhesion polymer in the aqueous solution. As previously discussed, the adhesion polymer may include peptides. Exemplary peptides may include, but are not limited to BSP, vitronectin, fibronectin, laminin, Type I and IV collagen, denatured collagen (gelatin), and like peptides, and mixtures thereof. Additionally, the peptides may be those having an RGD sequence. The coating may be, for example, Synthemax® II-SC (commercially available from Coming, Incorporated, Coming, NY).

[0095] According to embodiments of the present disclosure, methods for culturing cells on dissolvable foam scaffolds as described herein are also disclosed. Any type of cell may be cultured on the dissolvable foam scaffolds including, but not limited to, immortalized cells, primary culture cells, cancer cells, stem cells (e.g., embryonic or induced pluripotent), etc. The cells may be mammalian cells, avian cells, piscine cells, etc. The cells may be of any tissue type including, but not limited to, kidney, fibroblast, breast, skin, brain, ovary, lung, bone, nerve, muscle, cardiac, colorectal, pancreas, immune (e.g., B cell), blood, etc. The cells may be in any cultured form in the bag including disperse (e.g., freshly seeded), confluent, 2- dimensional, 3 -dimensional, spheroid, etc. Culturing cells on a dissolvable foam scaffold may include seeding cells on the dissolvable foam scaffold. Seeding cells on a dissolvable foam scaffold may include contacting the scaffold with a solution containing the cells. During seeding cells on the dissolvable foam scaffold, the cells enter the pores of the dissolvable foam scaffold. Where the dissolvable foam scaffold includes an adhesion polymer coating, cells may enter the pores of the dissolvable foam scaffold and attach to the scaffold material.

[0096] Culturing cells on dissolvable foam scaffolds may further include contacting the scaffolds with cell culture medium. Generally, contacting the scaffolds with cell culture medium includes placing cells to be cultured on the scaffolds in an environment with medium in which the cells are to be cultured. Contacting the scaffolds with cell culture medium may include pipetting cell culture medium onto the scaffolds, or submerging the scaffolds in cell culture medium, or passing cell culture media over the scaffolds in a continuous manner. Generally, as used herein, the term “continuous” refers to culturing cells with a consistent flow of cell culture medium into and out of the cell culture environment. Such passing cell culture media over the scaffolds in a continuous manner may include submerging the scaffolds in cell culture medium for a predetermined period of time, then removing at least some of the cell culture medium after the predetermined period of time and adding fresh cell culture medium such that the volume of cell culture medium in contact with the dissolvable foam scaffold remains substantially constant. Cell culture medium may be removed and replaced according to any predetermined schedule. For example, at least some of the cell culture medium may be removed and replaced every hour, or every 12 hours, or every 24 hours, or every 2 days, or every 3 days, or every 4 days, or every 5 days.

[0097] Cell culture medium may be for example, but is not limited to, sugars, salts, amino acids, serum (e.g., fetal bovine serum), antibiotics, growth factors, differentiation factors, colorant, or other desired factors. Exemplary cell culture medium includes Dulbecco’s Modified Eagle Medium (DMEM), Ham’s F12 Nutrient Mixture, Minimum Essential Media (MEM), RPMI Medium, Iscove's Modified Dulbecco’s Media (IMDM) Mesencult™-XF medium, and the like.

[0098] According to embodiments of the present disclosure, methods for harvesting cells from dissolvable foam scaffolds as described herein are also disclosed. Methods for harvesting cells as described herein may include digesting the dissolvable foam scaffold by exposing the dissolvable foam scaffold to an enzyme. As previously discussed, non- proteolytic enzymes suitable for digesting the foam scaffolds, harvesting cells, or both, include pectinolytic enzymes or pectinases, which are a heterogeneous group of related enzymes that hydrolyze the pectic substances. Commercially available sources of pectinases are generally multi-enzymatic, such as Pectinex™ ULTRA SP-L (commercially available fromNovozyme North American, Inc., Franklinton, NC), a pectolytic enzyme preparation produced from a selected strain of Aspergillus aculeatus. Pectinex™ ULTRA SP-L contains mainly polygalacturonase, (EC 3.2.1.15) pectintranseliminase (EC 4.2.2.2) and pectinesterase (EC: 3.1.1.11). The EC designation is the Enzyme Commission classification scheme for enzymes based on the chemical reactions the enzymes catalyze.

[0099] Exposing the dissolvable foam scaffold to an enzyme may include exposing the scaffold to enzyme concentrations of between about 1 and about 200 U. For example, the method may include exposing the scaffold to enzyme concentrations of between about 2 U and about 150 U, or between about 5 U and about 100 U, or even between about 10 U and about 75 U, and all values therebetween.

[00100] Methods for harvesting cells as described herein may further include exposing the material to a chelating agent. Exemplary chelating agents include, but are not limited to, ethylenediaminetetraacetic acid (EDTA), cyclohexanediaminetetraacetic (CDTA), ethylene glycol tetraacetic acid (EGTA), citric acid and tartaric acid. Exposing the dissolvable foam scaffold to a chelating agent may include exposing the scaffold to chelating agent concentrations of between about 1 mM and about 200 mM. For example, the method may include exposing the scaffold to chelating agent concentrations of between about 10 mM and about 150 mM, or between about 20 mM and about 100 mM, or even between about 25 mM and about 50 mM, and all values therebetween.

EXAMPLES

[00101] Embodiments of the present disclosure are further described below with respect to certain exemplary and specific embodiments thereof, which are illustrative only and not intended to be limiting.

Example 1 [00102] A first aqueous mixture containing 2.0 wt. % polygalacturonic acid (PGA) was prepared by dissolving about 162 grams of polygalacturonic acid sodium salt in demineralized water in an oil bath set at a temperature of 104°C. The aqueous mixture was cooled to room temperature. A second aqueous mixture was prepared by adding about 1.06 grams of CaCCh to about 24.52 grams of ultrapure water in the bowl of a KitchenAid mixer equipped with a wire loop whip. About 0.125 grams of TWEEN® 20 (commercially available from Sigma- Aldrich, St. Louis, MO) was also added to the bowl of the KitchenAid mixer. About 17.5 grams of sucrose was then added to the mixer bowl and mixed to facilitate dissolution of the sucrose in the second aqueous mixture. About 7.5 grams glycerol, about 1.94 grams Methocel HPMC Culminal 724 and the first aqueous mixture were added to form a combined aqueous mixture in the mixing bowl and mixed at a stir speed (speed 1 of the KitchenAid mixer) for about 5 minutes. The combined aqueous mixture was then whipped at a fast whipping speed (speed 10 of the KitchenAid mixer) for about 20 minutes to introduce air into the combined aqueous mixture. While continuing to whip the combined aqueous mixture, a solution of about 3.77 grams of gluconolactone (GDL) in about 30 mL of water was added to the mixing bowl and whipping was continued for about 1 minute.

[00103] An opaque white foam having a wet foam density of about 0.25 g/cc was obtained following the process discussed above. The foam was left uncovered in the mixing bowl at room temperature for about 1 hour to allow time for crosslinking to take place within the foam. The foam was then exposed to temperatures of about -80°C for about 16 hours to freeze the foam and then exposed to a temperature of -86°C and a pressure of 0.11 mbar for about 72 hours. The resulting foam was observed to have a dry foam density of about 0.04 to about 0.045 g/cc and was observed to be porous with highly interconnected pores. Figure 4 shows an SEM picture of the foam prepared in this Example 1. The composition of the resulting foam was determined to include about 1.3 wt. % PGA, about 0.78 wt. % HPM and a total solid content of about 2.08 wt. %. Example 2

[00104] The process as described in Example 1 was repeated except the second aqueous mixture was prepared by adding about 0.53 grams. The resulting foam was observed to be porous with highly interconnected pores. Figure 5 shows an SEM picture of the foam prepared in this Example 2.

Example 3 [00105] A first aqueous mixture containing 2.0 wt. % polygalacturonic acid (PGA) was prepared by dissolving about 162 grams of polygalacturonic acid sodium salt in demineralized water in an oil bath set at a temperature of 104°C. The aqueous mixture was cooled to room temperature. A second aqueous mixture was prepared by adding about 7.5 grams of glycerol to ultrapure water and heating under a microwave at 800W for about 30 seconds. About 0.97 grams of bovine gelatin was cold-swelled in about 5.8 mL of ultrapure water and then added to the second aqueous mixture and stirred until dissolution was observed. About 1.06 grams of CaCOs and about 0.125 grams of TWEEN® 20 were added to the second aqueous mixture. The second aqueous mixture was then sonicated for about 1 minute and then transferred to the bowl of a KitchenAid mixer equipped with a wire loop whip. About 17.5 grams sucrose and about 0.97 grams Methocel HPMC Culminal 724 were then added to the bowl of the KitchenAid mixer and the aqueous mixture was stirred for about 5 minutes. The first aqueous mixture containing 2.0 wt. % PGA were added to form a combined aqueous mixture in the mixing bowl and mixed at a stir speed (speed 1 of the KitchenAid mixer) for about 3 minutes. The combined aqueous mixture was then whipped at a fast whipping speed (speed 10 of the KitchenAid mixer) for about 20 minutes to introduce air into the combined aqueous mixture. While continuing to whip the combined aqueous mixture, a solution of about 3.77 grams of gluconolactone (GDL) in about 30 mL of water was added to the mixing bowl and whipping was continued for about 1 minute.

[00106] An opaque white foam was obtained following the process discussed above. The foam was left uncovered in the mixing bowl at room temperature for about 1 hour to allow time for crosslinking to take place within the foam. The foam was then exposed to temperatures of about -80°C for about 16 hours to freeze the foam and then exposed to a temperature of -86°C and a pressure of 0.11 mbar for about 72 hours. The resulting foam was observed to have a dry foam density of about 0.04 g/cc and was observed to be porous with highly interconnected pores. Figure 6 shows an SEM picture of the foam prepared in this Example 3. Example 4

[00107] The process as described in Example 3 was repeated except that about 0.97 grams of porcine gelatin, instead of bovine gelatin, was cold-swelled in about 5.8 mL of ultrapure water and then added to the second aqueous mixture and stirred until dissolution was observed. The resulting foam was observed to have a wet foam density of about 0.21 g/cc and a dry foam density of about 0.06 g/cc and was observed to be porous with highly interconnected pores. Figure 7 shows an SEM picture of the foam prepared in this Example 4.

Example 5 [00108] The process as described in Example 1 was repeated except the first aqueous mixture was prepared by dissolving about 172 grams of 3.0 wt. % polygalacturonic acid sodium salt in demineralized water in an oil bath set at a temperature of 104°C. Additionally, Methocel HPMC Culminal 724 was omitted from the second aqueous mixture. The resulting foam was observed to have a wet foam density of about 0.40 g/cc and a dry foam density of about 0.11 g/cc. The foam was observed to be less porous than the foam formed in Example 1 and the pores were less interconnected than the pores of the foam formed in Example 1. It is believed that the omission of Methocel HPMC Culminal 724, or any polymer having surface activity, reduced the porosity and the level of interconnectivity between the pores of the foam. Figure 8 shows an SEM picture of the foam prepared in this Example 5. Although a foam having a wet density of greater than about 0.40 g/cc and a dry density of greater than about 0.11 g/cc was demonstrated as being able to support culturing of cells, foams having a wet density of less than about 0.40 g/cc and a dry density of less than about 0.11 g/cc exhibited improved cell culturing conditions as compared to foams having wet and dry densities such as those possessed by the foam as formed in this Example 5.

Example 6

[00109] The process as described in Example 1 was repeated except the first aqueous mixture was prepared by dissolving about 162 grams of 1.59 wt. % polygalacturonic acid sodium salt in demineralized water in an oil bath set at a temperature of 104°C. Additionally, the second aqueous mixture was prepared by adding 0.53 grams of CaCCh to about 24.52 grams of ultrapure water and about 2.58 grams Methocel HPMC Culminal 724 was added to the second aqueous mixture. The resulting foam was observed to have a wet foam density of about 0.36 g/cc and a dry foam density of about 0.09 g/cc. Figure 9 shows an SEM picture of the foam prepared in this Example 6.

Example 7

[00110] The process as described in Example 1 was repeated except that sucrose was not added to the second aqueous mixture. The resulting foam was observed to have a wet foam density of about 0.23 g/cc and a dry foam density of about 0.03 g/cc. Figure 10 shows an SEM picture of the foam prepared in this Example 7.

Example 8

[00111] The process as described in Example 1 was repeated except the first aqueous mixture was prepared by dissolving about 162 grams of 2.59 wt. % polygalacturonic acid sodium salt in demineralized water in an oil bath set at a temperature of 104°C. Additionally, the second aqueous mixture was prepared by adding 0.97 grams Methocel HPMC Culminal 724 to the second aqueous mixture. The ratio of PGA to Methocel HPMC Culminal 724 in the combined aqueous mixture was controlled to be 81/19. The resulting foam was observed to have a wet foam density of about 0.18 g/cc and a dry foam density of about 0.057 g/cc. Figure 11 shows an SEM picture of the foam prepared in this Example 8.

Example 9

[00112] The process as described in Example 1 was repeated except the second aqueous mixture was prepared by adding 1.94 grams Dextran to the second aqueous mixture and Methocel HPMC Culminal 724 was omitted from the aqueous mixture. The resulting foam was observed to have a wet foam density of about 0.34 g/cc and a dry foam density of about 0.095 g/cc. The foam was observed to be less porous than the foam formed in Example 1 and the pores were less interconnected than the pores of the foam formed in Example 1. It is believed that the omission of Methocel HPMC Culminal 724, or any polymer having surface activity, reduced the level of interconnectivity between the pores of the foam. Furthermore, the addition of a polymer having no surface activity did not contribute to the formation of pores in the foam. Figure 12 shows an SEM picture of the foam prepared in this Example 9.

Example 10

[00113] The process as described in Example 1 was repeated except the second aqueous mixture was prepared by adding 1.94 grams Pluronic® Pl 23, instead of Methocel HPMC Culminal 724, to the second aqueous mixture. The ratio of PGA to Pluronic P123 in the combined aqueous mixture was controlled to be 62.5/37.5. The resulting foam was observed to have a wet foam density of about 0.18 g/cc and a dry foam density of about 0.03 g/cc and was observed to have a greater porosity than the foam as formed in Example 1. Figure 13 shows an SEM picture of the foam prepared in this Example 10.

Example 11 [00114] The process as described in Example 1 was repeated except the second aqueous mixture was prepared by adding a 50:50 weight ratio blend of Pluronic P123 and Dextran instead of Methocel HPMC Culminal 724. The resulting foam was observed to have a wet foam density of about 0.20 g/cc and a dry foam density of about 0.038 g/cc and was observed to have a greater porosity than the foam as formed in Example 1. Figure 14 shows an SEM picture of the foam prepared in this Example 11.

Example 12

[00115] The process as described in Example 11 was repeated to form multiple foams in which varied amounts of glycerol were added to the second aqueous mixture. In forming a first foam of this example, 6.5 grams of glycerol was added the second aqueous mixture. Glycerol constituted 19 wt. % of the total solid additives added to form the combined aqueous mixture. The resulting foam was observed to have a wet foam density of about 0.19 g/cc and a dry foam density of about 0.055 g/cc. In forming a second foam of this example, 7.5 grams of glycerol was added the second aqueous mixture. Glycerol constituted 22 wt. % of the total solid additives added to form the combined aqueous mixture. The resulting foam was observed to have a wet foam density of about 0.21 g/cc and a dry foam density of about 0.048 g/cc. In forming third first foam of this example, 19.44 grams of glycerol was added the second aqueous mixture. Glycerol constituted 42 wt. % of the total solid additives added to form the combined aqueous mixture. The resulting foam was observed to have a wet foam density of about 0.23 g/cc and a dry foam density of about 0.23 g/cc. In forming a fourth foam of this example, 29.16 grams of glycerol was added the second aqueous mixture. Glycerol constituted 52 wt. % of the total solid additives added to form the combined aqueous mixture. The resulting foam was observed to have a wet foam density of about 0.26 g/cc and a dry foam density of about 0.35 g/cc.

[00116] The four foams of Example 12 illustrate the effect of the amount of plasticizer on density and porosity when added during the formation of the foams. Slower drying, greater density and less porosity were observed with increasing plasticizer content. Also, as shown in Figure 15, the generally cylindrical shape of the foam was lost as the amount of glycerol increased above about 20-25 wt. % of the total solid additives added to form the second aqueous mixture. In Figure 15, foam 152 represents the sample with 19 wt. % glycerol, foam 154 represents the sample with 22 wt. % glycerol, foam 156 represents the sample with 42 wt. % glycerol, and foam 158 represents the sample with 52 wt. % glycerol. It was observed that porosity and interconnectivity of the pores of the foam was greatest when the amount of plasticizer added to the second aqueous mixture was less than about 52 wt. % of the total solid additives added to form the second aqueous mixture.

Example 13

[00117] The process as described in Example 1 was repeated except the second aqueous mixture was prepared by adding a 50:50 weight ratio blend of Pluronic P127 and Dextran. The resulting foam was observed to have a porosity and interconnectivity of pores similar to the foam prepared in Example 11. Figure 16 shows an SEM picture of the foam prepared in this Example 13.

Example 14

[00118] Foams formed in accordance with each of the processes in Examples 1-12 were coated with Synthemax® II-SC. A 250 pg/ml Synthemax® II-SC aqueous ethanol solution was prepared by adding about 5.0 mg of Coming® Synthemax® II-SC powder to about 20 mL of an aqueous ethanol solution having an ethanol: water ratio of 70:30. Each of the foams, which were about 2-3 mm thick and had diameters of about 22 mm, were placed in separate wells of Polystyrene 6-Well Cell Culture Plates. About 4.0 mL of the 250 pg/ml Synthemax® II-SC aqueous ethanol solution was added to each of the wells and the plates were then left undisturbed at room temperature for about 1.5 hours. Excess solution was removed from the wells and the foams were washed once with about 5.0 mL of a 70% aqueous ethanol. The Synthemax® II-SC coating was then crosslinked by adding about 4.0 mL of a 0.05% v/v glutaraldehyde in 70% aqueous ethanol (prepared by mixing 40pl of 25% glutaraldehyde solution in 6.0 mL water and 14 mL ethanol). The plates were left undisturbed at room temperature for about 1.5 hours to allow time for crosslinking to occur. The foam was then rinsed three times with ultrapure water.

Example 15

[00119] Foams formed in accordance with each of the processes in Examples 1-12 were coated with gelatin. A 0.1 wt. % gelatin solution was prepared by swelling about 500 mg of gelatin powder (from porcine skin) in ultrapure water followed by dissolution and homogenization in 20 mL of ultrapure water. Each of the foams, which were about 2-3 mm thick and had diameters of about 22 mm, were placed in separate wells of Polystyrene 6-Well Cell Culture Plates. About 4.0 mL of the gelatin solution was added to each of the wells and the plates were then left undisturbed at room temperature for about 1.5 hours. Excess solution was removed from the wells and the foams were washed once with about 5.0 mL of a 70% aqueous ethanol. The gelatin coating was then crosslinked by adding about 4.0 mL of a 0.05% v/v glutaraldehyde in 70% aqueous ethanol (prepared by mixing 50pl of 25% glutaraldehyde solution in 25 mL ultrapure water). The plates were left undisturbed at room temperature for about 1.5 hour to allow time for crosslinking to occur. The foam was then rinsed three times with ultrapure water.

Example 16

[00120] Culturing Vero cells on a foam formed in accordance with the process of Example 4 was investigated. Vero cells (ATCC® CCL-81, commercially available from ATCC, Manassas, VA) were cultured on cell culture plates in IMDM medium supplemented with 10% fetal bovine serum (FBS). The foam was cut into portions that were about 2-3 mm thick and had diameters of about 22 mm. The foam portions were sanitized in 70% aqueous ethanol for about 5.0 minutes, then placed in separate wells of a 6-Well Ultra-Low Attachment Cell Culture Plate. The foam portions were washed twice in ultrapure water and once in IMDM medium. Excess medium was removed from the wells before seeding.

[00121] Vero cells were harvested from the cell culture plates using trypsin, resuspended in IMDM medium and 150 pL containing about 100,000 cells were seeded in each of the foam portions which were positioned in the wells of the 6-Well Cell Culture Plate. The 6- Cell Culture Plate was placed in a cell culture incubator and, after about 2.0 hours, about 3.0 mL of IMDM medium was added to each well. After about 18 hours in the cell culture incubator, the foam portions were visualized using phase contrast microscopy. An image obtained from the phase contrast microscopy is depicted in Figure 17 which shows that the cells did not adhere to the uncoated foam portions, but instead formed spheroids in the pores of the foam portions. As such, it was determined that the dissolvable foam scaffolds of the present disclosure may be utilized to culture spheroids or non-adherent cells.

Example 17

[00122] Culturing Human Mesenchymal Stem Cells (hMSC) on a foam formed in accordance with the process of Example 4 and coated in accordance with the process of Example 14 was investigated. hMSC Passage 2 (commercially available from RoosterBio Inc., Frederick, MD) were cultured on cell culture plates in Mesencult™-XF medium (a serum-free medium commercially available from STEMCELL Technologies, Vancouver, BC, Canada). The foam was cut into portions that were about 2-3 mm thick and had diameters of about 22 mm. The foam portions were sanitized in 70% aqueous ethanol for about 5.0 minutes, then placed in separate wells of a 6-Well Ultra-Low Attachment Cell Culture Plate. The foam portions were washed twice in ultrapure water and once in the Mesencult™-XF medium. Excess medium was removed from the wells before seeding.

[00123] hMSC were harvested from the cell culture plates using trypsin, re-suspended in Mesencult™-XF medium and 150 pL containing about 100,000 cells were seeded in each of the foam portions which were positioned in the wells of the 6-Well Cell Culture Plate. The 6-Well Cell Culture Plate was placed in a cell culture incubator and, after about 2.0 hours, about 3.0 mL of Mesencult™-XF medium was added to each well. After about 18 hours in the cell culture incubator, cells were stained with 1 pg/mL Calcein-AM and visualized using fluorescence microscopy. An image obtained from the fluorescence microscopy is depicted in Figure 18 which shows that the cells were able to adhere to the foam portions, and spread within the pores of the foam portion. As such, it was determined that the dissolvable foam scaffolds coated with Coming® Synthemax® II-SC of the present disclosure may be utilized to culture adherent cells in addition to spheroids or non-adherent cells and that the scaffolds support cell culture in serum-free medium.

Example 18

[00124] Culturing Human Mesenchymal Stem Cells (hMSC) on a foam formed in accordance with the process of Example 4 and coated in accordance with the process of Example 15 was investigated. hMSC Passage 2 as used in Example 17 were cultured on cell culture plates in IMDM medium supplemented with 10% fetal bovine serum (FBS). The foam was cut into portions that were about 2-3 mm thick and had diameters of about 22 mm. The foam portions were sanitized in 70% aqueous ethanol for about 5.0 minutes, then placed in separate wells of a 6-Well Ultra-Low Attachment Cell Culture Plate. The foam portions were washed twice in ultrapure water and once in the Mesencult™-XF medium. Excess medium was removed from the wells before seeding.

[00125] hMSC were harvested from the cell culture plates using trypsin, re-suspended in IMDM medium and 150 pL containing about 100,000 cells were seeded in each of the foam portions which were positioned in the wells of the 6-Well Cell Culture Plate. The 6- Well Cell Culture Plate was placed in a cell culture incubator and, after about 2.0 hours, about 3.0 mL of IMDM medium was added to each well. After about 18 hours in the cell culture incubator, cells were stained with 1 pg/mL Calcein-AM and visualized using fluorescence microscopy. An image obtained from the fluorescence microscopy is depicted in Figure 19 which shows that the cells were able to adhere to the foam portions, and spread within the pores of the foam portion. Expansion of the hMSC cells was allowed to proceed on the foam for six days and again visualized using fluorescence microscopy. An image obtained from the fluorescence microscopy after six days is depicted in Figure 20 which shows cells adhered to the foam portions, and further spread within the pores of the foam portion. As such, it was determined that the dissolvable foam scaffolds coated with gelatin of the present disclosure may be utilized to culture adherent cells in addition to spheroids or non-adherent cells and that the scaffolds support cell culture in serum-containing medium.

Example 19

[00126] Expansion of Vero cells on a foam formed in accordance with the processes of Examples 2 and 4 and coated in accordance with the process of Example 15 was investigated. Vero cells as used in Example 16 were cultured on Tissue Culture Treated (TCT) plates in IMDM medium supplemented with 10% fetal bovine serum (FBS). The foam was cut into portions that were about 2-3 mm thick and had diameters of about 22 mm. The foam portions were sanitized in 70% aqueous ethanol for about 5.0 minutes, then placed in separate wells of a Polystyrene 6-Well Cell Culture Plate. The foam portions were washed twice in ultrapure water and once in the IMDM medium. Excess medium was removed from the wells before seeding.

[00127] Vero cells were harvested from the TCT plates using trypsin and re-suspended in IMDM medium. Some foam portions were seeded with 150 pL containing about 25,000 cells and other foam portions were seeded with 150 pL containing about 50,000 cells, wherein the foam portions were positioned in the well of the 6-Well Cell Culture Plate. The 6-Well Cell Culture Plate was placed in a cell culture incubator for about 6 days. After about 6 days, the medium was removed and the foams were dissolved by the addition to each of the wells of about 2.0 mL of a digestion solution containing about 50 U/mL pectinase and about 5.0 mM EDTA. The foam was observed to dissolve in under 5.0 minutes. Following dissolution of the foams, cells were counted using the trypan blue exclusion protocol as detailed in “Protocol for Performing a Trypan Blue Viability Test: Technical Reference Guide.” Lonza Cologne GmbH, September 2012, retrieved from: http://bio.lonza.com/uploads/tx_mwaxmarketingmaterial/Lonza_ BenchGuides_Protocol_for_ Performing a T rypan_Blue_Viability_T est T echnical Reference Guide. pdf.

[00128] It was observed that the cells colonized on all the pore surfaces of the foam portions. About 70- to 90-fold expansion was observed in the coated foam formed in accordance with the process of Example 4 and about 40 to 70 fold expansion was observed in the coated foam formed in accordance with the process of Example 2. As such, it was determined that the dissolvable foam scaffolds coated with gelatin of the present disclosure may be utilized for the expansion of Vero cells.

Example 20

[00129] Differentiation of Human Mesenchymal Stem Cells (hMSC) on a foam formed in accordance with the process of Example 4 and coated in accordance with the process of Example 15 was investigated. hMSC Passage 2 as used in Example 17 were cultured on cell culture plates in Mesencult™-XF medium. The foam was cut into portions that were about 2- 3 mm thick and had diameters of about 22 mm. The foam portions were sanitized in 70% aqueous ethanol for about 5.0 minutes, then placed in separate wells of a Polystyrene 6-Well Cell Culture Plate. The foam portions were washed twice in ultrapure water and once in the Mesencult™-XF medium. Excess medium was removed from the wells before seeding.

[00130] hMSC were harvested from the cell culture plates using trypsin, re-suspended in Mesencult™-XF medium and 150 pL containing about 100,000 cells were seeded in each of the foam portions which were positioned in the wells of the 6-Well Cell Culture Plate. The 6-Well Cell Culture Plate was placed in a cell culture incubator for about 3 days. After about 3 days, the Mesencult™-XF medium was removed and osteocyte differentiation medium, chondrocyte differentiation medium, and adipocyte differentiation medium (commercially available under the trade name StemPro™ Osteogenesis Differentiation Kit, StemPro™ Chondrogenesis Differentiation Kit and StemPro™ Adipogenesis Differentiation Kit respectfully from Thermo Fisher Scientific, Waltham, MA) was added to the wells, wherein each type of differentiation medium was added to foam portions in different wells than the other types of differentiation medium. After 3 weeks foam portions exposed to osteocyte differentiation medium were stained with Alizarin Red, foam portions exposed to chondrocyte differentiation medium were stained with Alcian Blue, and foam portions exposed to adipocyte differentiation medium were stained with Oil Red O. After staining, it was observed that hSMC cultured on dissolvable foam scaffolds coated with gelatin of the present disclosure maintain chondrogenic, osteogenic and adipogenic differentiation. As such, it was determined that cells cultured on dissolvable foam scaffolds of the present disclosure exhibit biological responses similar to biological responses of cells in-vivo.

Example 21

[00131] Expansion of Human Mesenchymal Stem Cells (hMSC) on a foam formed in accordance with the process of Examples 2, 11 and 13, and coated in accordance with the process of Example 14 was investigated. hMSC Passage 2 as used in Example 17 were cultured on cell culture plates in Mesencult™-XF medium. The foam was cut into portions that were about 2-3 mm thick and had diameters of about 22 mm. The foam portions were sanitized in 70% aqueous ethanol for about 5.0 minutes, then placed in separate wells of a 6- Well Ultra-Low Attachment Cell Culture Plate. The foam portions were washed twice in ultrapure water and once in the Mesencult™-XF medium. Excess medium was removed from the wells before seeding.

[00132] hMSC were harvested from the cell culture plates using trypsin, re-suspended in Mesencult™-XF medium and 150 pL containing about 100,000 cells were seeded in each of the foam portions which were positioned in the wells of the 6-Well Cell Culture Plate. The 6-Well Cell Culture Plate was placed in a cell culture incubator for about 7 days and medium was removed and replaced with fresh medium on day 4. After about 7 days, the medium was removed, and the foams were dissolved by the addition to each of the wells of about 2.0 mL of a digestion solution containing about 50 U/mL pectinase and about 5.0 mM EDTA. The foam was observed to dissolve in under 5.0 minutes. Following dissolution of the foams, cells were counted using the trypan blue exclusion protocol previously described. It was observed that cells colonized on all the pore surfaces of the foam portions and that expansion of hSMC on the dissolvable foam scaffolds coated with Coming® Synthemax® II-SC of the present disclosure was successfully accomplished.

Example 22

[00133] Comparison of culturing Human Mesenchymal Stem Cells (hMSC) in static conditions and in dynamic conditions on foams formed in accordance with the processes of Examples 2 and 11, and coated in accordance with the process of Example 14, was investigated. hMSC Passage 2 were cultured as in Example 17. hMSC were harvested from the cell culture plates using trypsin, re-suspended in Mesencult™-XF medium and 150 pL containing about 100,000 cells were seeded in twenty foam scaffolds as formed in Example 2 and in twenty foam scaffolds as formed in Example 11. The scaffolds were located in wells of 6-Well Cell Culture Plates which were placed in a cell culture incubator for about 2 hours. After about 2 hours, a 6-Well Cell Culture Plate containing scaffolds as formed in accordance with Example 2, and a 6-Well Cell Culture Plate containing scaffolds as formed in accordance with Example were removed from the incubator and the scaffolds were transferred to separate bioreactors. The other 6-Well Cell Culture Plates remained in the incubator. All of the scaffolds were kept under their respective conditions for about 6 days and were then dissolved by the addition of a digestion solution containing about 50 U/mL pectinase and about 5.0 mM EDTA. Following dissolution of the foams, cells were counted using the trypan blue exclusion protocol previously described. It was observed that the expansion of cells on the dissolvable foam scaffolds coated with Coming® Synthemax® II- SC of the present disclosure was similar under static conditions as under dynamic conditions.

Example 23

[00134] Multi-passage culturing of Human Mesenchymal Stem Cells (hMSC) was investigated. As described herein, the passage number of a cell culture is a record of the number of times the culture has been subcultured, i.e. harvested and reseeded. Thus, multipassage culturing in relation to the present disclosure describes a process wherein cells are harvested from one dissolvable foam scaffold and reseeded on a different dissolvable foam scaffold. hMSC were harvested from the cell culture plates using trypsin, re-suspended in Mesencult™-XF medium and 150 pL containing about 100,000 cells were seeded in a first set of foam scaffolds as formed in Example 2 and as coated in Example 14. The scaffolds were placed in Mesencult™-XF medium and placed in a cell culture incubator for about 6 days. After about 6 days, the scaffolds were dissolved by the addition of a digestion solution containing about 50 U/mL pectinase and about 5.0 mM EDTA. Following dissolution of the foams, cells were counted using the trypan blue exclusion protocol previously described. A solution containing about 100,000 cells that were harvested from the first set of scaffolds was then used to seed a second set of foam scaffolds as formed in Example 2 and as coated in Example 14. The scaffolds were placed in Mesencult™-XF medium and placed in a cell culture incubator for about 7 days. After about 7 days, the scaffolds were dissolved by the addition of a digestion solution containing about 50 U/mL pectinase and about 5.0 mM EDTA. Following dissolution of the foams, cells were counted using the trypan blue exclusion protocol. A solution containing about 100,000 cells harvested from the second set of scaffolds was then used to seed a third set of foam scaffolds as formed in Example 2 and as coated in Example 14. The scaffolds were placed in Mesencult™-XF medium and placed in a cell culture incubator for about 7 days. After about 7 days, the scaffolds were dissolved by the addition of a digestion solution containing about 50 U/mL pectinase and about 5.0 mM EDTA. Following dissolution of the foams, cells were counted using the trypan blue exclusion protocol and then seeded on cell culture plates where the cells were exposed to the differentiation medium, the chondrocyte differentiation medium, and the adipocyte differentiation medium used in Example 20. After 3 weeks cells exposed to osteocyte differentiation medium were stained with Alizarin Red, cells exposed to chondrocyte differentiation medium were stained with Alcian Blue, and cells exposed to adipocyte differentiation medium were stained with Oil Red O. After staining, it was observed that hSMC which experienced multi-passage culturing on dissolvable foam scaffolds coated with Coming® Synthemax® II-SC of the present disclosure maintain chondrogenic, osteogenic and adipogenic differentiation.

Example 24

[00135] Transfection of Human embryonic kidney (HEK) cells on a foam scaffold formed in accordance with the process of Example 11 and coated in accordance with the process of Example 14 was compared to the transfection of HEK cells on Coming® Synthemax® II-SC Dissolvable Microcarriers (commercially available from Coming Incorporated, Coming, NY). HEK cells were seeded on the Dissolvable Microcarriers. A first set of Dissolvable Microcarriers were placed in 6-Well Cell Culture Plates and exposed to IMDM medium supplemented with 10% fetal bovine semm (FBS). The 6-Well Cell Culture Plates were placed in a cell incubator and expanded in static conditions for about 3 days. A second set of Dissolvable Microcarriers were placed in a disposable spinner flask and suspended in IMDM medium supplemented with 10% fetal bovine serum (FBS) for about 3 days with intermittent stirring (stir for 15 minutes every 2.0 hours). After about 3 days, about 150 pL of a transfection reagent was added to the Dissolvable Microcarriers in the wells of the 6-Well Cell Culture Plates and about 1.0 mL of a transfection reagent was added to the spinner flask with continued intermittent stirring.

[00136] Portions of foam were seeded with HEK cells. Some foam portions were placed in 6-Well Cell Culture Plates, exposed to IMDM medium supplemented with 10% fetal bovine serum (FBS) and then the 6-Well Culture Plates were placed in a cell incubator for about 3 days. Other foam portions were placed in a chamber of a radial flow perfusion cartridge device for about 3 days. The perfusion cartridge device allowed for the continuous removal of spent IMDM medium supplemented with 10% fetal bovine serum (FBS) and addition of fresh IMDM medium supplemented with 10% fetal bovine serum (FBS) from the chamber. After about 3 days, about 150 pL of a transfection reagent was added to the foam portions in the wells of the 6-Well Cell Culture Plates and about 1.0 mL of a transfection reagent was added to the foam portions in the perfusion cartridge device.

[00137] After the addition of the transfection reagent, cells were harvested from the Dissolvable Microcarriers and from the foam portions and reporter gene expression levels were detected by measuring the response of green fluorescent protein (GFP) as reporter genes. GFP-positive percentage of the transfected HEK cells, which may be used as an indicator of transfection efficiency, was measured by flow cytometry. As used herein, the term "transfection efficiency" refers to the percentage of cells that have a given nucleic acid or biologically active molecule present within the cell after exposure to a transfection reagent. Figure 21 is a bar graph showing the GFP-positive percentage of the transfected HEK cells for each of the culture conditions. As shown: bar 1610 represents the GFP-positive percentage of the transfected HEK cells cultured on the dissolvable foams portions in the 6- Well Cell Culture Plates; bar 1620 represents the GFP-positive percentage of the transfected HEK cells cultured on the dissolvable foams portions in the perfusion cartridge device; bar 1630 represents the GFP-positive percentage of the transfected HEK cells cultured on Dissolvable Microcarriers in 6-Well Cell Culture Plates; and bar 1640 represents the GFP- positive percentage of the transfected HEK cells cultured on Dissolvable Microcarriers in the spinner flask. It was observed that cells cultured on dissolvable foam scaffolds coated with Coming® Synthemax® II-SC of the present disclosure exhibited greater transfection efficiency than cells cultured on microcarriers. Without wishing to be bound by any particular theory, it is believed that cells within pores of the foam scaffolds experienced greater exposure to the transfection reagent than cells attached to the surface of a microcarrier.

Example 25

[00138] Production of Adeno-Associated Virus (AAV) vectors on a foam scaffolds formed in accordance with the process of Example 11 and coated in accordance with the process of Example 14 was demonstrated. A first and a second set of foam scaffolds were seeded with 1 million 293aav cells and transferred to a chamber of a radial flow perfusion cartridge device where they were exposed to IMDM medium supplemented with 10% fetal bovine serum (FBS).

[00139] After about 24 hours, cells from the first set of foam scaffolds were transfected with an AAV-2 Helper Free Packaging System (commercially available from Cell Biolabs, Inc., San Diego, CA) using a Calcium Phosphate transfection method. Also, after about 24 hours, cells from the second set of foam scaffolds were transfected with an AAV-2 Helper Free Packaging System using a PEI method. For the Calcium Phosphate method, cells were incubated for about 18 hours with calcium phosphate/ DNA complexes prepared with a plasmid concentration of 6.4 pg/mL and a 1:1:1 molar ratio of plasmids. For the PEI method, cells on the foam scaffolds were transfected with 2pg plasmid/mL. In each of the PEI methods, PEI/DNA ratios of 2/1 and 1:1:1 molar ratio of plasmids were used.

[00140] The radial flow perfusion cartridge devices were operated at a perfusion rate of 20 mL/min for about 2 hours and then at 5 mL/min for about 16 hours. For all sets of cells, medium was removed and replaced with fresh medium after about 18 hours. Cells were then incubated further and harvested 72 hours after transfection. The foam scaffolds were collected and dissolved by the addition of a digestion solution containing about 50 U/mL pectinase and about 5.0 mM EDTA. Following dissolution of the foam scaffolds, cells were collected using centrifugation and washed in dPBS. A portion of the cells were kept for flow cytometry analysis, and the remaining cells were lyzed using a 20mM tris pH8, 150mM NaCl, 0.1% sodium deoxy cholate buffer supplemented with 50U/mL benzonase. [00141] After about 30 minutes of incubation at 37°C, viral extracts were clarified by centrifugation for about 5 min at 14,000 rpm. Viral titers were measured using the AAV -2 ELISA assay (commercially available from PROGEN Biotechnik GmbH, Heidelberg, Germany).

[00142] Transfection efficiency was analyzed using flow cytometry and good transfection efficiency was observed. Figure 22 is a bar graph showing the GFP-positive percentage of the transfected cells for each of the sets of foam scaffolds. As shown: bar 1710 represents the GFP-positive percentage of the cells transfected using the Calcium Phosphate transfection method in which transfection method in which transfection efficiency was measured to be about 86.4%; and bar 1720 represents the GFP-positive percentage of the cells transfected using the PEI transfection method in which transfection efficiency was measured to be about 73.8%.

[00143] Virus titer was also measured using ELISA assay. Figure 23 is a bar graph showing the number of viral particles (vp) per set of foam scaffold. As shown: bar 1810 represents the viral particles of the cells transfected using the Calcium Phosphate transfection method in which 8.7 x 10 ¹¹ viral particles were measured; and bar 1820 represents viral particles of the cells transfected using the PEI transfection method in which 5.7 x 10 ¹¹ viral particles were measured. Figure 24 is a bar graph showing the number of viral particles per cell per set of foam scaffold. As shown: bar 1910 represents the viral parti cles/cell of the cells transfected using the Calcium Phosphate transfection method in which 1.17 x 10 ⁵ viral particles/cell were measured; and bar 1920 represents viral particles/cell of the cells transfected using the PEI transfection method in which 6.8 x 10 ⁴ viral particles/cell were measured.

[00144] Finally, the functionality of the viral vectors was assessed by testing the extracts capacity to induce GFP expression in the infected HEK 293 cells. Viral vector infectivity was assessed by infecting HEK 293 cells with extracts prepared using 10 ⁵ viral particles/cell to infect. About 72 hours after infection, GFP-positive percentage of the infected HEK cells was measured by flow cytometry. Infection was observed for cells from each of the sets of foam scaffolds. GFP expression was used to identify the efficiency of gene transfer, which for the present example ranged from about 10% to about 26%. As such, it was concluded that functional AAV vectors can be produced on foam scaffolds as disclosed herein. Figure 25 is a bar graph showing the fraction of cells exhibiting GFP expression for each of the sets of foam scaffolds after infection. As shown: bar 2010 represents the fraction of cells exhibiting GFP expression for the cells transfected using the Calcium Phosphate transfection method in which about 26% of the cells exhibited GFP expression; and bar 2020 represents the fraction of cells exhibiting GFP expression for the cells transfected using the PEI transfection method in which about 10% of the cells showed GFP expression.

Example 26

[00145] Figure 26 is an illustration of an experimental design for investigating the impact of previous cell culture conditions on cell growth performance, transfection efficiency, and viral vector production performance. This experimental design, explained below, represents the procedures used in the following Example to produce the data shown in Figures 28-33. As shown in Figure 26, a seed train procedure involving one or two colony passages (Pl and P2, respectively) using dissolvable scaffolds according to the present disclosure was compared to a cell culture expansion on a 2D surface. The dissolvable scaffold used is a PGA scaffold as disclosed herein.

[00146] For these experiments, HEK293T cells (ATCC® number: CRL3216™) are prepared by growing them on a Coming CellBIND® surface in IMDM supplemented with 10% fetal bovine serum (FBS), penicillin/streptomycine, and 2 mM glutamine. Cells were incubated in a cell culture incubator at 37°C in a water-saturated atmosphere supplemented with 5% CO2. Cells were then harvested using trypsin before they reach confluency.

[00147] For static cell seeding on dissolvable scaffolds, rehydrated PGA scaffolds were equilibrated in culture medium, then foam pieces were drained from the excess of medium and placed in a Corning® Ultra-Low Attachment (ULA) Multiple Well Plate (6 well plate). A cell suspension (2*10 ⁶ cells/mL) was then dispensed drop-wise in the scaffolds (500 pL cell suspension for 1 mL scaffold). For HEK293T cells, acceptable seeding densities range from l*10 ⁵ to 5*10 ⁶ cell/ mL of scaffold. Seeded scaffolds were then incubated for 2 hours at 37°C in a cell culture incubator, then 4 mL of complete medium was added to each well. For seeding on dissolvable scaffolds in a perfusion bioreactor, the scaffolds were placed in the culture chamber of the perfusion reactor then l*10 ⁶ cells per cm ³ of scaffold to be seeded are added to the medium tank. Perfusion speed was set to 1 reactor volume per minute for 3 hours, and then set back to the minimal speed needed to maintain a constant oxygenation.

[00148] Cell transfection for AAV-GFP vector production was performed in the dissolvable scaffold by transfecting HEK293 derived cells with the 3 plasmids from the AAV-2 Helper Free Packaging System from Cell Biolabs, Inc. (Ref# VPK-402). Transfection on the 2D CellBIND® surface is performed as follows: the well (of the 6 well plate) was seeded 3 days prior to transfection with 50,000 cells, 2 pg of an equimolar ratio of the p AAV-GFP, pRC2 and pHelper plasmid mix are incubated for 15 minutes with 4 pg of PEI - Pro (Polyplus Ref. #115-010) and then dispensed drop wise on the cells in the well. After 18 hours of incubation, the medium is renewed, and cells are incubated for 72 additional hours during viral vector production.

[00149] For transfection of cells growing in static conditions in dissolvable scaffolds, the transfection mix is prepared as described previously for the 2D surface. The culture medium is drained from the scaffold, then 500 pL of transfection mix/mL of scaffolds are added dropwise to the scaffold piece. After 4 hours of incubation in a cell culture incubator, 4 mL of complete medium were added to the well. After 14 more hours of incubation, the medium is renewed, and cells are incubated for 72 additional hours during viral vector production. For transfection in perfused conditions in dissolvable scaffolds, the transfection mix is prepared as previously described, using equimolar ratio of the 3 plasmids and a PEI/DNA ratio of 2:1. A total amount of 2 pg DNA/mL of medium is used for the transfection. The transfection mix is added to the medium tank and the perfusion speed is set to 1 vol/min for 18 hours. After 18 hours of incubation, the medium is renewed, perfusion speed is set back to minimal speed allowing to maintain a constant oxygenation and cells are incubated for 72 additional hours during viral vector production.

[00150] Cell harvesting from the dissolvable scaffolds was performed as follows. The cell culture medium was aspirated, and the scaffold was washed using D-PBS. Dissolution buffer (5 mM EDTA, 50 U/mL pectinase) was then added to the scaffold (10 mL dissolution buffer/mL of scaffold). After 5 minutes of incubation at room temperature and complete scaffold dissolution, the cells in suspension in the dissolution buffer were pelleted by centrifugation and washed with D-PBS. Harvested cells were then able to be used for reseeding or analysis. [00151] The impact of the above cell culture methods (2D surface and dissolvable scaffold) on cell performance and AAV vector production were investigated using the experiment shown in Figure 26. Specifically, three culture conditions were compared: (1) 293T cells harvested from a 2D surface (2D, in Figure 26); (2) 293T cells grown in the dissolvable scaffold for 1 passage (Pl, in Figure 26); and (3) 293T cells grown in dissolvable PGA scaffold for 2 passages (P2, in Figure 26). For Pl, HEK293T cells were harvested from a CellBIND® surface, and 300,000 of the harvested cells were seeded in Synthemax®-coated PGA scaffolds and expanded for 4 days in static conditions leading to the harvest of 2 million cells after scaffold dissolution. Acceptable seeding densities range from I / IO ⁴ to l*10 ⁶ cells per slice. Maximal cell number at harvest should ideally be in the range of 6-8 *10 ⁶ cell /slice, the time needed to reach this density depending on initial cell density and cell doubling time in the culture conditions used. For P2, HEK293T cells were harvested from a CellBIND® surface, 300,000 of the harvested cells were seeded in Synthemax®-coated PGA scaffolds and expanded for 4 days in static conditions leading to the harvest of 2 million cells after scaffold dissolution. 300,000 of those harvested cells were then seeded again in Synthemax®-coated PGA scaffolds and expanded for 4 more days in static conditions, leading again to the harvest of 2 million cells.

[00152] Cells from each of the above three culture origins (2D, Pl, and P2 in Figure 26) were used to seed 2D CellBIND® 6-well plates (50,000 cells/well) or dissolvable scaffold slices in 6-well plates (300,000 cells/slice) for a final expansion and transfection. After 3 days of expansion, cells in 2D conditions or in dissolvable scaffolds were transfected with the AAV plasmids as described above. After 3 more days, cells were harvested and cell growth performance, transfection efficiency, and AAV-GFP vector production were characterized. Figure 27 compares the cell growth performance of cells from different origins (2D, Pl, and P2) that were then finally expanded on a 2D surface, where the growth performance is measured in terms of cell growth ratio. As shown in Figure 27, the cell growth performance is relatively comparable for cells from 2D, Pl and P2 origins, ranging from about 75% to about 100%, with the cells originating from the dissolvable scaffolds (Pl and P2) being slightly lower than the cells originating from the 2D surface.

[00153] In Figure 28, the cell growth performance, again in terms of cell growth ratio, is compared for cells from the three different origins (2D, Pl, and P2) that are finally expanded on a dissolvable scaffold. The results are again comparable, with the Pl and P2 cells performing about equally with the 2D-originated cells. However, Figure 28 shows that the dissolvable scaffold-originated cells (Pl and P2) performed better when their final expansion was also performed on a dissolvable scaffold, as opposed to the final expansion being on a 2D surface (see Figure 27). Figure 29 shows fluorescence microscopy images of green fluorescence protein (GFP) expression for cells from the three different origin conditions (2D, Pl, and P2) that were transfected in 2D conditions (upper row) and in dissolvable scaffolds (lower row).

[00154] Figure 30 shows transfection efficiency ratios for cells transfected on the 2D surface as measured using flow cytometry in 2D for the cells from the different origins (2D, Pl, and P2). The efficiency ratios are based on GFP expression ratios at harvest. The overall transfection efficiency in 2D seems comparable for 2D, Pl, and P2 origin conditions. Similarly, Figure 31 shows transfection efficiency ratios for cells transfected in dissolvable scaffolds for the cells from the different origins (2D, Pl, and P2). Again, the overall transfection efficiency in the dissolvable scaffold is comparable for 2D, Pl, and P2 origin conditions.

[00155] The viral vector titers obtained in 2D and in dissolvable scaffolds for the cells from the different origins was measured using ELISA assay (from Progen). Figure 32 presents the number of viral particles expressed per cell (VP/Cell) obtained for cells finally grown and transfected in 2D, comparing the performance obtained with cells originating from each of the three origin conditions. The results indicate that virus production remains comparable for cells previously grown in dissolvable scaffolds for 1 or 2 passages (Pl or P2, respectively). Figure 33, however, shows the results obtained for cells finally grown and transfected in dissolvable scaffolds, comparing the performance obtained with cells originating from each of the three origin conditions. In this case, the performance observed for Pl and P2 conditions is significantly better than the performance of cells that originated from a 2D surface. Without wishing to be bound by theory, it is believed that this improved performance could be linked to a better adaptation of the cells to the culture conditions during the final expansion and transfection. Thus, while even when improvements are not necessarily seen in cell growth numbers as a result from using a seed train without requiring cell adaptation for a new substrate, as discussed above with respect to Figures 27 and 28, improvements can still be seen in viral vector production.

Example 27

[00156] The following is a protocol for a seed train method according to an example embodiment of this disclosure, similar to Figure 2. This example seed train method is for the seeding of 200 liters of dissolvable scaffold. To start, a working cell bank vial containing 2.5 xlO ⁷ viable cells is thawed and the cells are transferred to a bioreactor containing 25 mL of dissolvable scaffold. The seeding phase can then be performed as described above. Cells are then incubated for 5 days, recirculation is set, and culture conditions are controlled so that oxygenation and nutrient levels are kept in optimal ranges, and cells culture wastes kept below deleterious ranges. Under these conditions, HEK293T cells should exit lag phase 12- 16 hours after seeding. With a generation time of approximately 20 to 25 hours, which is commonly described for this cell line under normal conditions, cell harvest 5 days after seeding should at least provide 5*10 ⁸ cells and remain below cell confluency known to have a deleterious effect on transfection performance for this cell line. Cell harvest should be performed as described above and cells reseeded after washing in a bioreactor containing 500 mL of dissolvable scaffold. Cell expansion of 5*10 ⁸ cells for 5 days should at least produce 12.5* 10 ⁹ sub-confluent cells. l *10 ¹⁰ of harvested cells can be reseeded in a bio reactor containing 10 liters of dissolvable scaffold and produce in 5 days more than the 2xlO ⁿ cells needed to seed a bioreactor containing 200 liters of dissolvable scaffold.

[00157] The same seed train using a regular 225 cm ² cell culture plate (2D surface) would require 5 flasks for the first step (cell seeding at 22,250 cells/cm ² in 1125 cm ² ), this first step should provide 5*10 ⁸ cells in 5 days, usable to seed 89 flasks for the second step (seeding at 25,000 cells/cm ² ). After 5 days, the second amplification step should provide I xlO ¹⁰ cells and should allow to reseed 1,778 225 cm ² flasks (see Table 1). After 5 days of expansion, this last step should provide the 2xlO ⁿ cells the seeding of a bioreactor containing the 200 liters of dissolvable scaffold. Several technically competent people would be required for this seed train process and this would represent many hours of work. In addition, the footprint required for the 2D vessels is large.

Example 28

[00158] A two-passage cell culture seed train was carried out and the cell number was plotted versus the days of the cell culture in Figure 34. As shown in Figure 34, cells were harvested at day 6 using Pectinase/EDTA and reseeded. Next, cells were harvested a second time at day 11 (5 days after the first harvest), centrifuged, re-suspended in medium and 100K cells per foam scaffold were reseeded. Transfection was performed on day 14, and a final harvest was performed on day 18. The cumulated cell expansion from this seed train is shown in Figure 35, depicted in the fold expansion over days. As shown, this example seed train method resulted in almost 10,000-fold expansion of cells.

[00159] Illustrative Implementations

[00160] The following is a description of various aspects of implementations of the disclosed subject matter. Each aspect may include one or more of the various features, characteristics, or advantages of the disclosed subject matter. The implementations are intended to illustrate a few aspects of the disclosed subject matter and should not be considered a comprehensive or exhaustive description of all possible implementations.

[00161] According to an aspect 1 of the present disclosure, a dissolvable foam scaffold for cell culture is provided. The dissolvable foam scaffold comprises an ionotropically crosslinked polygalacturonic acid compound selected from at least one of: pectic acid; partially esterified pectic acid, partially amidated pectic acid and salts thereof; and at least one first water-soluble polymer having surface activity.

[00162] According to an aspect 2 of the present disclosure, the dissolvable foam scaffold of aspect 1 is provided further comprising an adhesion polymer coating.

[00163] According to an aspect 3 of the present disclosure, the dissolvable foam scaffold of aspect 2 is provided wherein the adhesion polymer coating comprises peptides. [00164] According to an aspect 4 of the present disclosure, the dissolvable foam scaffold of aspect 2 is provided wherein the adhesion polymer coating comprises peptides selected from the group consisting of BSP, vitronectin, fibronectin, laminin, Type I collagen, Type IV collagen, denatured collagen and mixtures thereof.

[00165] According to an aspect 5 of the present disclosure, the dissolvable foam scaffold of aspect 2 is provided wherein the adhesion polymer coating comprises Synthemax® II-SC.

[00166] According to an aspect 6 of the present disclosure, the dissolvable foam scaffold of any of aspects 1-5 is provided wherein the at least one first polymer has a hydrophilic-lipophilic balance (HLB) of greater than about 8.

[00167] According to an aspect 7 of the present disclosure, the dissolvable foam scaffold of any of aspects 1-6 is provided wherein the at least one first polymer has a hydrophilic-lipophilic balance (HLB) of greater than about 10.

[00168] According to an aspect 8 of the present disclosure, the dissolvable foam scaffold of any of aspects 1-7 is provided wherein the at least one first polymer may has a hydrophilic-lipophilic balance (HLB) of between about 10 and about 40.

[00169] According to an aspect 9 of the present disclosure, the dissolvable foam scaffold of any of aspects 1-8 is provided wherein the at least one first polymer comprises a cellulose derivative.

[00170] According to an aspect 10 of the present disclosure, the dissolvable foam scaffold of aspect 9 is provided wherein the cellulose derivative is selected from the group consisting of hydroxy ethylcellulose (HEC), hydroxypropylcellulose (HPC), methylcellulose (MC), hydroxyethylmethylcellulose (HEMC), and hydroxypropyl-methylcellulose (HPMC).

[00171] According to an aspect 11 of the present disclosure, the dissolvable foam scaffold of any of aspects 1-8 is provided wherein the at least one first polymer comprises a protein. [00172] According to an aspect 12 of the present disclosure, the dissolvable foam scaffold of aspect 11 is provided wherein the protein is selected from the group consisting of bovine serum albumin (BSA), gelatine, casein and hydrophobins.

[00173] According to an aspect 13 of the present disclosure, the dissolvable foam scaffold of any of aspects 1-8 is provided wherein the at least one first polymer comprises a synthetic amphiphilic polymer.

[00174] According to an aspect 14 of the present disclosure, the dissolvable foam scaffold of aspect 13 is provided wherein the synthetic amphiphilic polymer comprises a poloxamer.

[00175] According to an aspect 15 of the present disclosure, the dissolvable foam scaffold of any of aspects 1-14 is provided comprising at least two first water-soluble polymers having surface activity.

[00176] According to an aspect 16 of the present disclosure, the dissolvable foam scaffold of any of aspects 1-15 is provided further comprising at least one second polymer having no surface activity.

[00177] According to an aspect 17 of the present disclosure, the dissolvable foam scaffold of aspect 16 is provided wherein the at least one second polymer comprises a synthetic polymer.

[00178] According to an aspect 18 of the present disclosure, the dissolvable foam scaffold of aspect 17 is provided wherein the synthetic polymer is selected from the group consisting of polyethylene glycol, polyvinyl pyrrolidone, polyvinyl alcohol, carboxyvinyl polymer, polyacrylic acid, polyacrylamide, homopolymer and copolymer of N-(2- Hydroxypropyl) methacrylamide, polyvinyl methyl ether-maleic anhydride, and polyethylene oxide/polypropylene oxide block copolymers.

[00179] According to an aspect 19 of the present disclosure, the dissolvable foam scaffold of aspect 16 is provided wherein the at least one second polymer comprises a semisynthetic polymer. [00180] According to an aspect 20 of the present disclosure, the dissolvable foam scaffold of aspect 19 is provided wherein the semisynthetic polymer is selected from the group consisting of dextran derivatives, carboxymethyl cellulose, hydroxyethyl cellulose and derivatives, methylcellulose and derivatives, ethylcellulose cellulose, ethyl hydroxyethyl cellulose, and hydroxypropyl cellulose.

[00181] According to an aspect 21 of the present disclosure, the dissolvable foam scaffold of aspect 16 is provided wherein the at least one second polymer comprises a natural polymer.

[00182] According to an aspect 22 of the present disclosure, the dissolvable foam scaffold of aspect 21 is provided wherein the natural polymer is selected from the group consisting of starch, starch derivatives, curdlan, pullulan, gellan gum, xanthan gum, dextran, albumin, casein, caseinates, gelatin, agar, alginates, carrageenan, guar gum, guar gum derivatives, locust bean gum, hyaluronic acid, and chondroitin sulfate.

[00183] According to an aspect 23 of the present disclosure, the dissolvable foam scaffold of any of aspects 1-22 is provided further comprising a water soluble plasticizer.

[00184] According to an aspect 24 of the present disclosure, the dissolvable foam scaffold of aspect 23 is provided wherein the water soluble plasticizer is selected from the group consisting of glycerol, polyhydric alcohol, sorbitol, ethylene glycol, propylene glycol, polyethylene glycol and combinations thereof.

[00185] According to an aspect 25 of the present disclosure, the dissolvable foam scaffold of any of aspects 23-24 is provided comprising less than about 55 wt. % water soluble plasticizer.

[00186] According to an aspect 26 of the present disclosure, the dissolvable foam scaffold of any of aspects 23-25 is provided comprising between about 15 wt. % and about 55 wt. % water soluble plasticizer.

[00187] According to an aspect 27 of the present disclosure, the dissolvable foam scaffold of any of aspects 1-26 is provided comprising a porosity of between about 85% and about 96%. [00188] According to an aspect 28 of the present disclosure, the dissolvable foam scaffold of any of aspects 1-27 is provided comprising an average pore size diameter of between about 50 pm and about 500 pm.

[00189] According to an aspect 29 of the present disclosure, the dissolvable foam scaffold of any of aspects 1-28 is provided comprising an average pore size diameter of between about 75 pm and about 450 pm.

[00190] According to an aspect 30 of the present disclosure, the dissolvable foam scaffold of any of aspects 1-29 is provided comprising an average pore size diameter of between about 100 pm and about 400 pm.

[00191] According to an aspect 31 of the present disclosure, the dissolvable foam scaffold of any of aspects 1-30 is provided comprising a wet density of less than about 0.40 g/cc.

[00192] According to an aspect 32 of the present disclosure, the dissolvable foam scaffold of any of aspects 1-31 is provided comprising a wet density of less than about 0.30 g/cc.

[00193] According to an aspect 33 of the present disclosure, the dissolvable foam scaffold of any of aspects 1-32 is provided comprising a wet density of between about 0.16 g/cc and about 0.40 g/cc.

[00194] According to an aspect 34 of the present disclosure, the dissolvable foam scaffold of any of aspects 1-33 is provided comprising a dry density of less than about 0.20 g/cc.

[00195] According to an aspect 35 of the present disclosure, the dissolvable foam scaffold of any of aspects 1-34 is provided comprising a dry density of less than about 0.10 g/cc.

[00196] According to an aspect 36 of the present disclosure, the dissolvable foam scaffold of any of aspects 1-35 is provided comprising a dry density of between about 0.02 g/cc and about 0.20 g/cc. [00197] According to an aspect 37 of the present disclosure, the dissolvable foam scaffold of any of aspects 1-36 is provided comprising an open pore architecture.

[00198] According to an aspect 38 of the present disclosure, the dissolvable foam scaffold of any of aspects 1-37 is provided wherein digestion of the dissolvable foam scaffold is complete in less than about 1 hour.

[00199] According to an aspect 39 of the present disclosure, the dissolvable foam scaffold of any of aspects 1-38 is provided wherein digestion of the dissolvable foam scaffold is complete in less than about 15 minutes.

[00200] According to an aspect 40 of the present disclosure, a method for forming a dissolvable foam scaffold is provided. The method comprises: forming a first aqueous mixture by adding a polygalacturonic acid compound selected from at least one of: pectic acid; partially esterified pectic acid, partially amidated pectic acid and salts thereof to an aqueous solution; forming a second aqueous mixture by adding at least one first water- soluble polymer having surface activity and a divalent metal salt to an aqueous solution; combining the first aqueous mixture with second first aqueous mixture to form a combined aqueous mixture; adding a gel inducing agent to the combined aqueous mixture; and introducing gas bubbles into the combined aqueous mixture to form a foam scaffold.

[00201] According to an aspect 41 of the present disclosure, the method of aspect 40 is provided wherein forming a second aqueous mixture further comprises adding at least one second polymer having no surface activity.

[00202] According to an aspect 42 of the present disclosure, the method of aspect 41 is provided wherein adding at least one first polymer and at least one second polymer comprises adding between about 35% and about 65% of the at least one first polymer and between about 35% and about 65% of the at least one second polymer.

[00203] According to an aspect 43 of the present disclosure, the method of any of aspects 40-42 is provided wherein forming a second aqueous mixture comprises adding at least two first water-soluble polymers having surface activity. [00204] According to an aspect 44 of the present disclosure, the method of any of aspects 40-43 is provided wherein the divalent metal salt comprises: a cation selected from the group consisting of magnesium, calcium, zinc, strontium, barium, and combinations thereof; and an anion selected from the group consisting of oxalates, tartrates, phosphates, carbonates, citrates, and combinations thereof.

[00205] According to an aspect 45 of the present disclosure, the method of any of aspects 40-43 is provided wherein forming a second aqueous mixture further comprises adding a water soluble plasticizer to the second aqueous mixture.

[00206] According to an aspect 46 of the present disclosure, the method of aspect 45 is provided wherein the water soluble plasticizer is selected from the group consisting of glycerol, polyhydric alcohol, sorbitol, ethylene glycol, propylene glycol, polyethylene glycol and combinations thereof.

[00207] According to an aspect 47 of the present disclosure, the method of any of aspects 45-46 is provided wherein the water soluble plasticizer comprises less than about 55 wt. % of the total solid additives of the second aqueous mixture.

[00208] According to an aspect 48 of the present disclosure, the method of any of aspects 45-47 is provided wherein the water soluble plasticizer comprises between about 15 wt. % and about 55 wt. % of the total solid additives of the second aqueous mixture.

[00209] According to an aspect 49 of the present disclosure, the method of any of aspects 40-48 is provided wherein forming a second aqueous mixture further comprises adding an emulsifying agent to the second aqueous mixture.

[00210] According to an aspect 49 of the present disclosure, the method of any of aspects 40-48 is provided wherein forming a second aqueous mixture further comprises adding an emulsifying agent to the second aqueous mixture.

[00211] According to an aspect 50 of the present disclosure, the method of any of aspects 40-49 is provided wherein forming a second aqueous mixture further comprises adding at least one leachable solid to the second aqueous mixture. [00212] According to an aspect 51 of the present disclosure, the method of aspect 50 is provided wherein the at least one leachable solid is selected from the group consisting of salts, biocompatible mono and disaccharides and water-soluble proteins.

[00213] According to an aspect 52 of the present disclosure, the method of any of aspects 40-51 is provided wherein the gel inducing agent is selected from the group consisting of lactic acid lactone, glycolic acid lactone, glucono delta lactone and acid anhydrides.

[00214] According to an aspect 53 of the present disclosure, the method of any of aspects 40-52 is provided, further comprising coating the dissolvable foam scaffold with an adhesion polymer coating.

[00215] According to an aspect 54 of the present disclosure, the method of aspect 53 is provided wherein the adhesion polymer coating comprises peptides.

[00216] According to an aspect 55 of the present disclosure, the method of aspect 53 is provided wherein the adhesion polymer coating comprises peptides selected from the group consisting of BSP, vitronectin, fibronectin, laminin, Type I collagen, Type IV collagen, denatured collagen and mixtures thereof.

[00217] According to an aspect 56 of the present disclosure, the method of aspect 53 is provided wherein the adhesion polymer coating comprises Synthemax® II-SC.

[00218] According to an aspect 57 of the present disclosure, a method for culturing cells on a dissolvable foam scaffold is provided. The method comprises: seeding cells on a dissolvable foam scaffold such that cells enter pores of the dissolvable foam scaffold, the dissolvable scaffold comprising: an ionotropically crosslinked polygalacturonic acid compound selected from at least one of: pectic acid; partially esterified pectic acid, partially amidated pectic acid and salts thereof; and at least one first water-soluble polymer having surface activity; and contacting the dissolvable foam scaffold with cell culture medium.

[00219] According to an aspect 58 of the present disclosure, the method of aspect 57 is provided wherein cells aggregate in the pores of the dissolvable foam scaffold to form spheroids. [00220] According to an aspect 59 of the present disclosure, the method of any of aspects 57-58 is provided wherein the dissolvable foam scaffold comprises an adhesion polymer coating and wherein seeding cells on a dissolvable foam scaffold comprises adhering cells to the surface of the dissolvable foam scaffold.

[00221] According to an aspect 60 of the present disclosure, the method of any of aspects 57-59 is provided wherein contacting the dissolvable foam scaffold with cell culture medium comprises submerging the dissolvable foam scaffold in cell culture medium.

[00222] According to an aspect 61 of the present disclosure, the method of any of aspects 57-60 is provided wherein contacting the dissolvable foam scaffold with cell culture medium comprises continuously passing cell culture medium over the dissolvable foam scaffold.

[00223] According to an aspect 62 of the present disclosure, the method of aspect 61 is provided wherein continuously passing cell culture medium over the dissolvable foam scaffold comprises removing at least some of the cell culture medium from contact with the dissolvable foam scaffold and contacting the dissolvable foam scaffold with fresh cell culture medium such that the volume of cell culture medium in contact with the dissolvable foam scaffold remains substantially constant.

[00224] According to an aspect 63 of the present disclosure, a method of harvesting cells from a dissolvable foam scaffold is provided. The method comprises: digesting the dissolvable foam scaffold by exposing the dissolvable foam scaffold to an enzyme; the dissolvable scaffold comprising: an ionotropically crosslinked polygalacturonic acid compound selected from at least one of: pectic acid; partially esterified pectic acid, partially amidated pectic acid and salts thereof; and at least one first water-soluble polymer having surface activity; and exposing the dissolvable foam scaffold to a chelating agent.

[00225] According to an aspect 64 of the present disclosure, the method of aspect 63 is provided wherein the enzyme comprises a non-proteolytic enzyme.

[00226] According to an aspect 65 of the present disclosure, the method of aspect 64 is provided wherein the non-proteolytic enzyme is selected from the group consisting of pectinolytic enzymes and pectinases. [00227] According to an aspect 66 of the present disclosure, the method of any of aspects 63-65 is provided wherein digesting the dissolvable foam scaffold comprises exposing the dissolvable foam scaffold to between about 1 U and about 200 U of the enzyme.

[00228] According to an aspect 67 of the present disclosure, the method of any of aspects 63-66 is provided comprising exposing the dissolvable foam scaffold to between about 1 mM and about 200 mM of the chelating agent.

[00229] According to an aspect 68 of the present disclosure, a foamed scaffold product formed from a composition is provided. The composition comprises: an ionotropically crosslinked polygalacturonic acid compound selected from at least one of: pectic acid; partially esterified pectic acid, partially amidated pectic acid and salts thereof; at least one first water-soluble polymer having surface activity; and less than about 55 wt. % water soluble plasticizer.

[00230] According to an aspect 69 of the present disclosure, the foamed scaffold product of aspect 68 is provided further comprising an adhesion polymer coating.

[00231] According to an aspect 70 of the present disclosure, the foamed scaffold product of aspect 69 is provided wherein the adhesion polymer coating comprises peptides.

[00232] According to an aspect 71 of the present disclosure, the foamed scaffold product of aspect 69 is provided wherein the adhesion polymer coating comprises peptides selected from the group consisting of BSP, vitronectin, fibronectin, laminin, Type I collagen, Type IV collagen, denatured collagen and mixtures thereof.

[00233] According to an aspect 72 of the present disclosure, the foamed scaffold product of aspect 69 is provided wherein the adhesion polymer coating comprises Synthemax® II-SC.

[00234] According to an aspect 73 of the present disclosure, the foamed scaffold product of any of aspects 68-72 is provided wherein the at least one first polymer has a hydrophilic-lipophilic balance (HLB) of greater than about 8. [00235] According to an aspect 74 of the present disclosure, the foamed scaffold product of any of aspects 68-73 is provided wherein the at least one first polymer has a hydrophilic-lipophilic balance (HLB) of greater than about 10.

[00236] According to an aspect 75 of the present disclosure, the foamed scaffold product of any of aspects 68-74 is provided wherein the at least one first polymer may has a hydrophilic-lipophilic balance (HLB) of between about 10 and about 40.

[00237] According to an aspect 76 of the present disclosure, the foamed scaffold product of any of aspects 68-75 is provided wherein the at least one first polymer comprises a cellulose derivative.

[00238] According to an aspect 77 of the present disclosure, the foamed scaffold product of aspect 76 is provided wherein the cellulose derivative is selected from the group consisting of hydroxy ethylcellulose (HEC), hydroxypropylcellulose (HPC), methylcellulose (MC), hydroxyethylmethylcellulose (HEMC), and hydroxypropyl-methylcellulose (HPMC).

[00239] According to an aspect 78 of the present disclosure, the foamed scaffold product of any of aspects 68-75 is provided wherein the at least one first polymer comprises a protein.

[00240] According to an aspect 79 of the present disclosure, the foamed scaffold product of aspect 78 is provided wherein the protein is selected from the group consisting of bovine serum albumin (BSA), gelatine, casein and hydrophobins.

[00241] According to an aspect 80 of the present disclosure, the foamed scaffold product of any of aspects 68-75 is provided wherein the at least one first polymer comprises a synthetic amphiphilic polymer.

[00242] According to an aspect 81 of the present disclosure, the foamed scaffold product of aspect 80 is provided wherein the synthetic amphiphilic polymer comprises a poloxamer.

[00243] According to an aspect 82 of the present disclosure, the foamed scaffold product of any of aspects 68-81 is provided comprising at least two first water-soluble polymers having surface activity. [00244] According to an aspect 83 of the present disclosure, the foamed scaffold product of any of aspects 68-82 is provided wherein the foam scaffold composition further comprises at least one second polymer having no surface activity.

[00245] According to an aspect 84 of the present disclosure, the foamed scaffold product of aspect 83 is provided wherein the at least one second polymer comprises a synthetic polymer.

[00246] According to an aspect 85 of the present disclosure, the foamed scaffold product of aspect 84 is provided wherein the synthetic polymer is selected from the group consisting of polyethylene glycol, polyvinyl pyrrolidone, polyvinyl alcohol, carboxyvinyl polymer, polyacrylic acid, polyacrylamide, homopolymer and copolymer of N-(2- Hydroxypropyl) methacrylamide, polyvinyl methyl ether-maleic anhydride, and polyethylene oxide/polypropylene oxide block copolymers.

[00247] According to an aspect 86 of the present disclosure, the foamed scaffold product of aspect 83 is provided wherein the at least one second polymer comprises a semisynthetic polymer.

[00248] According to an aspect 87 of the present disclosure, the foamed scaffold product of aspect 86 is provided wherein the semisynthetic polymer is selected from the group consisting of dextran derivatives, carboxymethyl cellulose, hydroxyethyl cellulose and derivatives, methylcellulose and derivatives, ethylcellulose cellulose, ethyl hydroxyethyl cellulose, and hydroxypropyl cellulose.

[00249] According to an aspect 88 of the present disclosure, the foamed scaffold product of aspect 83 is provided wherein the at least one second polymer comprises a natural polymer.

[00250] According to an aspect 89 of the present disclosure, the foamed scaffold product of aspect 88 is provided wherein the natural polymer is selected from the group consisting of starch, starch derivatives, curdlan, pullulan, gellan gum, xanthan gum, dextran, albumin, casein, caseinates, gelatin, agar, alginates, carrageenan, guar gum, guar gum derivatives, locust bean gum, hyaluronic acid, and chondroitin sulfate. [00251] According to an aspect 90 of the present disclosure, the foamed scaffold product of any of aspects 68-89 is provided wherein the water soluble plasticizer is selected from the group consisting of glycerol, polyhydric alcohol, sorbitol, ethylene glycol, propylene glycol, polyethylene glycol and combinations thereof.

[00252] According to an aspect 91 of the present disclosure, the foamed scaffold product of any of aspects 68-90 is provided comprising between about 15 wt. % and about 55 wt. % water soluble plasticizer.

[00253] According to an aspect 92 of the present disclosure, the foamed scaffold product of any of aspects 68-91 is provided comprising a porosity of between about 85% and about 96%.

[00254] According to an aspect 93 of the present disclosure, the foamed scaffold product of any of aspects 68-92 is provided comprising an average pore size diameter of between about 50 pm and about 500 pm.

[00255] According to an aspect 94 of the present disclosure, the foamed scaffold product of any of aspects 68-93 is provided comprising an average pore size diameter of between about 75 pm and about 450 pm.

[00256] According to an aspect 95 of the present disclosure, the foamed scaffold product of any of aspects 68-94 is provided comprising an average pore size diameter of between about 100 pm and about 400 pm.

[00257] According to an aspect 96 of the present disclosure, the foamed scaffold product of any of aspects 68-95 is provided comprising a wet density of less than about 0.40 g/cc.

[00258] According to an aspect 97 of the present disclosure, the foamed scaffold product of any of aspects 68-96 is provided comprising a wet density of less than about 0.30 g/cc.

[00259] According to an aspect 98 of the present disclosure, the foamed scaffold product of any of aspects 68-97 is provided comprising a wet density of between about 0.16 g/cc and about 0.40 g/cc. [00260] According to an aspect 99 of the present disclosure, the foamed scaffold product of any of aspects 68-98 is provided comprising a dry density of less than about 0.20 g/cc.

[00261] According to an aspect 100 of the present disclosure, the foamed scaffold product of any of aspects 68-99 is provided comprising a dry density of less than about 0.10 g/cc.

[00262] According to an aspect 101 of the present disclosure, the foamed scaffold product of any of aspects 68-100 is provided comprising a dry density of between about 0.02 g/cc and about 0.20 g/cc.

[00263] According to an aspect 102 of the present disclosure, the foamed scaffold product of any of aspects 68-101 is provided comprising an open pore architecture.

[00264] According to an aspect 103 of the present disclosure, a method of cell seed train expansion is provided comprising: providing a first cell culture substrate comprising a dissolvable foam scaffold; delivering cells and a cell culture media to the first cell culture substrate, the cells being seeded on or in the dissolvable foam scaffold of the first cell culture substrate; controlling environmental conditions and composition of the cell culture media to promote culturing of the cells on the first cell culture substrate; dissolving the dissolvable foam scaffold of the first cell culture substrate to form a solution containing the cells; harvesting the cells from the solution; and reseeding at least a portion of the cells that were harvested onto a second cell culture substrate of the dissolvable foam scaffold, wherein the dissolvable foam scaffold of the first cell culture substrate is the same material as the dissolvable foam scaffold of the second cell culture substrate.

[00265] According to an aspect 104 of the present disclosure, the method of Aspect 103 is provided, wherein the first and second cell culture substrates are three-dimensional cell culture scaffolds.

[00266] According to an aspect 105 of the present disclosure, the method of Aspect 103 or 104 is provided, further comprising: delivering cell culture media to the second cell culture substrate; and controlling environmental conditions and composition of the cell culture media to promote culturing of the cells in the dissolvable foam scaffold of the second cell culture substrate.

[00267] According to an aspect 106 of the present disclosure, the method of Aspect 105, further comprising dissolving the dissolvable foam scaffold of the second cell culture substrate and harvesting the cells therefrom.

[00268] According to an aspect 107 of the present disclosure, the method of Aspect 106 is provided, further comprising reseeding at least a portion of the cells that were harvested from the second cell culture substrate onto a third cell culture substrate of the dissolvable foam scaffold, wherein the dissolvable foam scaffold of the third cell culture substrate is the same material as the dissolvable foam scaffold of the second cell culture substrate.

[00269] According to an aspect 108 of the present disclosure, the method of Aspect 103 is provided, further comprising thawing a cryopreserved cell bank to provide the cells for delivery to the first cell culture substrate.

[00270] According to an aspect 109 of the present disclosure, the method of Aspect 103 or Aspect 108 is provided, wherein the cells are obtained from a cryovial.

[00271] According to an aspect 110 of the present disclosure, the method of Aspect 103 is provided, wherein the cells are seeded on the first cell culture substrate such that the cells enter pores of the dissolvable foam scaffold.

[00272] According to an aspect 111 of the present disclosure, the method of Aspect 103 is provided, wherein the dissolvable foam scaffold is disposed in a container configured to hold the cell culture media.

[00273] According to an aspect 112 of the present disclosure, the method of Aspect 111 is provided, wherein the container is a perfusion bioreactor.

[00274] According to an aspect 113 of the present disclosure, the method of Aspect 103 is provided, wherein the cells comprise adherent or semi-adherent cells. [00275] According to an aspect 114 of the present disclosure, the method of Aspect 103 is provided, wherein the cells comprise Vero cells, Human embryonic kidney (HEK) cells, or Human Mesenchymal Stem Cells (hMSC).

[00276] According to an aspect 115 of the present disclosure, the method of any of Aspects 103-114 is provided, wherein at least one of the first and second cell culture substrate are arranged as a packed bed within a bioreactor.

[00277] According to an aspect 116 of the present disclosure, the method of any of Aspects 103-115 is provided, wherein the dissolvable foam scaffold is dissolved via exposure to an enzyme.

[00278] According to an aspect 117 of the present disclosure, the method of Aspect

116 is provided, wherein the enzyme comprises a non-proteolytic enzyme.

[00279] According to an aspect 118 of the present disclosure, the method of Aspect

117 is provided, wherein the non-proteolytic enzyme is selected from the group consisting of pectinolytic enzymes and pectinases.

[00280] According to an aspect 119 of the present disclosure, the method of any of Aspects 103-116, wherein a volume of the second cell culture substrate is greater than a volume of the first cell culture substrate.

[00281] According to an aspect 120 of the present disclosure, the method of Aspect 119 is provided, wherein a volume of the third cell culture substrate is greater than the volume of the second cell culture substrate.

[00282] According to an aspect 121 of the present disclosure, the method of any of Aspects 103-120 is provided, further comprising transfecting the cells after being reseeded.

[00283] According to an aspect 122 of the present disclosure, the method of any of Aspects 103-121 is provided, wherein the dissolvable foam scaffold comprises: an ionotropically crosslinked polygalacturonic acid compound selected from at least one of: pectic acid; partially esterified pectic acid, partially amidated pectic acid and salts thereof; and at least one first water-soluble polymer having surface activity. [00284] According to an aspect 123 of the present disclosure, the method of Aspect 122 is provided, the dissolvable foam scaffold further comprising a water soluble plasticizer.

[00285] According to an aspect 124 of the present disclosure, the method of Aspect 123 is provided, the dissolvable foam scaffold comprising less than about 55 wt. % water soluble plasticizer.

[00286] According to an aspect 125 of the present disclosure, the method of any of Aspects 122-124 is provided, the dissolvable foam scaffold further comprising an adhesion polymer coating.

[00287] According to an aspect 126 of the present disclosure, the method of Aspect 125 is provided, wherein the adhesion polymer coating comprises peptides.

[00288] According to an aspect 127 of the present disclosure, the method of Aspect 125 is provided, wherein the adhesion polymer coating comprises peptides selected from the group consisting of BSP, vitronectin, fibronectin, laminin, Type I collagen, Type IV collagen, denatured collagen and mixtures thereof.

[00289] According to an aspect 128 of the present disclosure, the method of Aspect 125 is provided, wherein the adhesion polymer coating comprises Synthemax® II- SC.

[00290] According to an aspect 129 of the present disclosure, the method of any of Aspects 122-128 is provided, wherein the at least one first polymer has a hydrophilic- lipophilic balance (HLB) of greater than about 8.

[00291] According to an aspect 130 of the present disclosure, the method of any of Aspects 122-129, wherein the at least one first polymer comprises a cellulose derivative.

[00292] According to an aspect 131 of the present disclosure, the method of any of Aspects 122-129 is provided, wherein the at least one first polymer comprises a protein.

[00293] According to an aspect 132 of the present disclosure, the method of any of Aspects 122-129 is provided, wherein the at least one first polymer comprises a synthetic amphiphilic polymer. [00294] According to an aspect 133 of the present disclosure, the method of any of Aspects 122-132 is provided, the dissolvable foam scaffold further comprising at least two first water-soluble polymers having surface activity.

[00295] According to an aspect 134 of the present disclosure, the method of any of Aspects 122-133 is provided, the dissolvable foam scaffold further comprising at least one second polymer having no surface activity.

[00296] According to an aspect 135 of the present disclosure, the method of Aspect 134 is provided, wherein the at least one second polymer comprises a synthetic polymer.

[00297] According to an aspect 136 of the present disclosure, the method of Aspect 134 is provided, wherein the at least one second polymer comprises a semisynthetic polymer.

[00298] According to an aspect 137 of the present disclosure, the method of Aspect 134 is provided, wherein the at least one second polymer comprises a natural polymer.

[00299] According to an aspect 138 of the present disclosure, the method of any of Aspects 122-137 is provided, the dissolvable foam scaffold further comprising an average pore size diameter of between about 50 pm and about 500 pm.

[00300] According to an aspect 139 of the present disclosure, the method of any of Aspects 122-138 is provided, the dissolvable foam scaffold further comprising a wet density of less than about 0.40 g/cc.

[00301] According to an aspect 140 of the present disclosure, the method of any of Aspects 122-139 is provided, the dissolvable foam scaffold further comprising an open pore architecture.

[00302] According to an aspect 141 of the present disclosure, the method of any of Aspects 122-140 is provided, wherein digestion of the dissolvable foam scaffold is complete in less than about 1 hour.

[00303] According to an aspect 142 of the present disclosure, a method of cell seed train expansion for scaling a cell sample to a production scale reactor is provided, the method comprising: expanding the cell sample containing cells on a first dissolvable foam scaffold; expanding at least a portion of the cells harvested from the first dissolvable foam scaffold onto a second dissolvable foam scaffold; seeding at least a portion of the cells harvested from at least one of the first dissolvable foam scaffold and the second dissolvable foam scaffold onto a third dissolvable foam scaffold, wherein the first, second, and third dissolvable foam scaffold comprise the same scaffold material.

[00304] According to an aspect 143 of the present disclosure, the method of Aspect 142 is provided, wherein the expanding on the first dissolvable foam scaffolds comprises: seeding the cells on the first dissolvable foam scaffold; expanding the cells to increase the number of the cells; dissolving the first dissolvable foam scaffold to form a first harvest solution; and harvesting the cells from the first harvest solution.

[00305] According to an aspect 144 of the present disclosure, the method of Aspect 142 or 143 is provided, wherein the expanding on the second dissolvable foam scaffolds comprises: seeding the cells on the second dissolvable foam scaffold; expanding the cells to increase the number of the cells; dissolving the second dissolvable foam scaffold to form a second harvest solution; and harvesting the cells from the second harvest solution.

[00306] According to an aspect 145 of the present disclosure, the method of any of Aspects 142-144 is provided, wherein a volume of the second dissolvable foam scaffold is greater than a volume of the first dissolvable foam scaffold.

[00307] According to an aspect 146 of the present disclosure, the method of any of Aspects 142-145 is provided, wherein the first dissolvable foam scaffold has a volume of about 10 mL to about 300 mL, about 10 mL to about 100 mL, or about 25 mL to about 50 mL.

[00308] According to an aspect 147 of the present disclosure, the method of any of Aspects 142-146 is provided, wherein the second dissolvable foam scaffold has a volume of from about 100 mL to about 1000 mL, from about 200 mL to about 900 mL, from about 300 mL to about 800 mL, from about 400 mL to about 600 mL, from about 450 mL to about 550 mL, or about 500 mL.

[00309] According to an aspect 148 of the present disclosure, the method of any of Aspects 142-147 is provided, wherein the third dissolvable foam scaffold has a volume of from about 1 L to about 500 L, from about 1 L to about 100 L, from about 100 L to about 200 L, from about 200 L to about 300 L, from about 300 L to about 400 L, from about 400 L to about 500 L, at least about 500 L, from about 1 L to about 20 L, from about 5 L to about 15 L, or about 10 L.

[00310] According to an aspect 149 of the present disclosure, the method of any of Aspects 142-148 is provided, wherein at least one of the first, second, and third dissolvable foam scaffolds comprise: an ionotropically crosslinked polygalacturonic acid compound selected from at least one of: pectic acid; partially esterified pectic acid, partially amidated pectic acid and salts thereof; and at least one first water-soluble polymer having surface activity.

[00311] While the present disclosure includes a limited number of embodiments, those skilled in the art, having benefit of this disclosure, will appreciate that other embodiments can be devised which do not depart from the scope of the present disclosure.